
# Examine<sup>®</sup> Skin, Hair & Nails Supplement Guide



## **Table of Contents**

- Introduction
- Combos
- Primary Supplements
- Secondary Supplements
- Promising Supplements
- Unproven Supplements
- Inadvisable Supplements
- FAQ

### Introduction

Few sales pitches will get people reaching for their wallets faster than promising that "this will make you more attractive". We all want to look our best, as shown by the billions of dollars we collectively spend each year on the vast array of products that tout ingredients to preserve and improve the appearance of skin, hair, and nails. Most of those are topical, but some can be taken orally, and in this guide we'll be looking at both types.

Like the world of supplements, the world of cosmetics is a bit like the Wild West — there are very <u>few rules</u>, and everyone is trying to make a quick buck. Beware of misleading claims: a skincare product might proudly state it has been "dermatologist-tested", but what does this mean really? Just that a dermatologist tested the product in some unspecified way. What it does *not* mean is that the product was shown to have any cosmetic benefit whatsoever.

But wait! This product also states that its purpose is to, let's say, reduce wrinkles. Here again, however, the product states only one thing: its purpose. There's no guarantee of its *efficacy* for this purpose. Wrinkles, dry hair, and brittle nails can be symptoms of a health condition, but they are not considered health conditions in themselves; this helps explain why, in the US, cosmetics are regulated more like supplements than like drugs. The FDA regulates the legality of the ingredients and the accuracy of the labels — but doesn't evaluate efficacy.

One unique aspect of aesthetic health, though, is that you sometimes need only a mirror to see whether a product works. With most areas of health, you have to rely on laboratory tests; or you might try to judge how you *feel* after taking the product for a while, in which case the truth gets obscured by the placebo effect and faulty memory. But if a facial moisturizer failed to moisturize or a hair conditioner to condition, they probably wouldn't be sold for very long.

However, while a mirror may be enough to assess short-term changes in some areas, to track long-term changes you should take pictures (under the same conditions; lighting, notably, can make a big difference). And even then, it can be hard to be sure if a product is working or not, because anti-aging products claim to *slow down* apparent aging; none claims to be able keep you looking twenty until you reach your hundredth birthday.

But then, what can you do? Spend hundreds of dollars a year on products that may or may not make you look better than you would have without them?

This is where science comes in: it can allow us to evaluate different health aspects of skin, hair, and nails using clinical trials, and how those factors are affected by various products.

## Your skin

At a cellular level, your skin has three main enemies: DNA damage and dysfunction, oxidative stress, and inflammation leading to damage to, breakdown of, and improper folding of proteins. As we'll see in this guide, it is plausible that some nutrients and other bioactive components in foods could delay skin aging by playing an antioxidant, anti-inflammatory, or structural role.

Aging skin is characterized by altered pigmentation and a decrease in thickness, moisture, and elasticity. This decrease results in creasing and the formation of permanent wrinkles.

The two main extrinsic causes of skin degradation are photoaging (caused by UV radiation from the

sun<sup>[1][2][3]</sup> or tanning beds) and smoking, but air pollution is also a plausible factor. Of course, even if you lived in an air-filtered, sunproof bubble, you'd still get some wrinkles eventually, due to your body's natural breakdown with age. The pull of gravity may also play a role, over years, but this topic is still debated.

As we said, science can allow us to evaluate different health aspects of our skin. By employing imaging technology to measure small differences in skin health, researchers can track small changes to the skin over several months (and thus assess the efficacy of a product). Wrinkles, notably, can be measured in various ways: depth, area, volume, and other less common measurements.

To assess the skin's function, researchers frequently measure the skin's rate of water loss: *transepidermal water loss* (TEWL) provides important information about the integrity of the skin barrier. To measure skin moisture at different points in time, researchers usually measure the skin's conductance (its ability to conduct electricity) or capacitance (its ability to hold an electric charge). Of the instruments used for this purpose, the corneometer is perhaps the most popular.

Unfortunately, aging isn't the only enemy. The skin is also commonly afflicted by conditions characterized by lesions with various causes and characteristics. The most common of those conditions is <u>acne</u>. Alas, experts still don't agree on a method or a scale for assessing acne severity. Still, counting the number of lesions may at least provide useful information.


Another common skin condition is <u>atopic dermatitis</u>, a type of <u>eczema</u> that affects many children and a growing number of adults. In atopic dermatitis, the skin barrier is compromised and the skin is dry, itchy, and inflamed — which leads to unsightly red patches.

#### **Facts about atopic dermatitis**


TENDS TO OCCUR ALONGSIDE...



#### MOST COMMON LOCATIONS VARY BY AGE FOR...



#### THINGS THAT MAKE SYMPTOMS WORSE



Reference: Weidinger and Novak. Lancet. 2016.[13]

Researchers have designed different scales to assess the severity of atopic dermatitis and other types of eczema, as well as of other skin conditions such as <u>rosacea</u> and <u>psoriasis</u>. [14][15]

#### Q Digging Deeper: Grading eczema

To grade the severity of eczema, researchers use scoring scales, such as the Scoring Atopic Dermatitis (SCORAD) index and Eczema Area and Severity Index (EASI).

SCORAD combines information on the extent (A), intensity (B), and subjective symptoms (C) of the

disease.


To determine *extent*, the sites affected by eczema are shaded on a drawing of the body to calculate the affected area as a percentage of the whole body. The maximum score is 100%.

To determine *intensity*, a representative area is selected and six signs of inflammation — redness, dryness, swelling, oozing/crusting, lichenification (skin thickening), and scratch marks — are assessed on a three-point scale, giving a maximum score of 18 points.

Subjective symptoms include itchiness and sleeplessness, both of which are rated on a ten-point scale and combined for a maximum score of 20 points.

The SCORAD score is calculated as A/5 + 7B/2 + C. A score of <25 is mild, 25–50 is moderate, and >50 is severe.

*EASI*, as the name indicates, is simpler: it only takes into account the percentage of the body covered by atopic dermatitis and the physical severity of the symptoms. EASI scores range from 0 to 72.



In the case of lesions and disrupted skin barrier, certain bacteria may exacerbate or even initiate a skin condition. This is another area where food and supplements may be of use, since the proper function of the immune system depends notably on nutrients.

## Your hair

Your hair and skin are very different, to be sure, but since hair follicles are embedded in the skin, your skin (particularly your dermal papillae, whose blood vessels nourish hair follicles) plays a vital role in the health of your hair.

The foremost hair issue is <u>alopecia</u> (better known as *hair loss*), and the most common type of alopecia is <u>androgenetic/androgenic alopecia</u> (commonly known as <u>male-pattern baldness</u>, even though <u>it can also affect women</u>). It is characterized by the miniaturization of hair follicles and a shift toward *vellus hair* (thin and short hair found more commonly prior to puberty) and away from *terminal hair* (adult-stage hair). [22]

Androgenetic alopecia has a strong genetic component and is related to androgens (hence the name), but inflammation also plays a prominent role and may be affected by dietary and lifestyle factors. There's a plausible role for various vitamins and minerals in the prevention of hair loss, and the consumption of a dietary pattern close to the nutrient-rich Mediterranean diet has been associated with less hair loss. [23][24]

Alopecia areata is another form of hair loss. It involves severe inflammation and is especially hard on the psyche. With androgenetic alopecia, hair thins and recedes slowly, so that people have time to come to terms with it; in males past a certain age, it is even seen as natural, if undesirable. Alopecia areata, on the other hand, is an <u>autoimmune disorder</u> that strikes fast and looks unnatural: the immune system attacks and destroys healthy hair follicles, causing not only hair thinning but also small yet obvious bald spots, apparently randomly placed on the scalp. [25]

Aside from hair loss, there are two main hair issues: breakage and graying.

To measure breakage, researchers have been known to get inventive. One particular method involves a standardized tool that pulls out a small amount of hair (ouch?). The fewer hairs get pulled out, the stronger your hair. Other methods such as simply measuring the number of natural breaks on your scalp are less invasive, though possibly confounded by hat-wearing.

Another hair issue that many people wish they could do more about is graying. A common trope in popular culture and everyday life is that people can worry themselves gray. While this isn't a well-understood subject, a mouse study found that stress can indeed lead to hair graying through activation of the sympathetic nervous system and resultant depletion of melanocyte stem cells responsible for pigmentation. [54] It is plausible that oxidative stress (which is, under certain limits, a normal aspect of your body's metabolism) could play a part as well, but more research is needed.

### Your nails

Most oral supplements touted for their hair benefits also claim to benefit your nails. This association is due to keratin (a fibrous protein) being the key structural component of both. Unfortunately, studies that actually looked at the effect of supplementation on nails are scarce.

### The bottom line

So to recap: maintaining a healthy weight, getting enough nutrients, reducing stress, and not smoking can help your skin and hair (and probably nails) look their best. Wait ... that's basic health advice that everyone should be following anyway. Yes, it is probable that one of the many benefits of healthy living is that it makes you better looking! That's convenient, and for some people might even be a greater motivation than life extension.

Still, for those of us who are playing catch-up or want to optimize, the basics may not be enough, and supplements and topical products can help. But which to choose? This guide doesn't review branded products but rather ingredients. If you know that a given ingredient is effective and innocuous at a certain dose, you can look for products that contain (enough but not too much of) this ingredient.

Beware, though: an ingredient may have been shown to be effective when swallowed but not when applied to the skin, and vice versa. Collagen, for instance, is easily digestible, but you can't replenish the collagen *in* your skin by applying collagen *to* your skin.

Another pitfall is that supplements and cosmetics often use "proprietary blends" to hide how much of each ingredient you're getting. A skin-care product might advertise that it contains *HYALURONIC ACID* (in big, bold letters), when in fact it contains so little as to be meaningless.

So to be safe, seek out brands whose websites provide detailed ingredient information. On a product's label, look for ingredients that have been shown to work in this dose, form, and delivery method.

Wyatt Brown, researcher

### **Combos**

### **Core Combo**

For days when your *sun exposure is less than 2 hours*, apply a broad-spectrum <u>sunscreen</u> or moisturizer with sunscreen that has an SPF of at least 30 in the morning to exposed skin. If you have <u>acne</u> or oily skin, select an oil-free sunscreen.

For days when your *sun exposure is 2 hours or greater*, use a broad-spectrum sunscreen with an SPF of at least 30. If you burn easily, at least 40.

Apply 30–90 mL (1–3 fl. oz.) to exposed skin to ensure adequate coverage. If you will be in the sun longer than 2 hours, reapply at least every 2 hours. More frequent applications are needed if you have been swimming or sweating. An SPF of 70+ may be more optimal for people who burn easily or forget to reapply consistently. If using a sunscreen spray, rub it in to even out the application.

#### Tip: Try one combo alone for a few weeks

Taking too many supplements at once may prevent you from determining which ones are truly working. Start with just one of the combos suggested here for a couple of weeks before you consider making any modification, such as adding another supplement, altering a supplements dosage, or incorporating the supplements from an additional combo.

When adding another supplement to your regimen, be methodical. For example, you may wish to take all the supplements from two combos. Select the combo that you wish to try first and take this for a couple of weeks. Then, add one supplement from the second combo and wait another week to see how it affects you. Continue this process until you've added all the supplements you wish to.

If a supplement appears in two combos you wish to combine, don't stack the doses; instead, combine the ranges. For instance, if the range is 2–4 mg in one combo and 3–6 mg in the other, your new range becomes 2–6 mg. Always start with the lower end of the range — especially in this case, since the reason why one of the ranges has a lower ceiling in one combo may be due to a synergy with another supplement in the same combo. Reading through the full supplement entry may help you decide which dose to aim for, but if you're not sure, lower is usually safer.

## **Specialized Combos**

### For people seeking protection from the sun

In addition to using a broad-spectrum <u>sunscreen</u>, take 7.5 mg of <u>Polypodium leucotomos</u> per kilogram of body weight per day (3.4 mg/lb/day).

*P. leucotomos* does not have to be taken daily to benefit from its UV-protective effects. Consume one dose 24-hours prior to sun exposure and a second the day of, at least 2 hours prior to sun exposure. If your sun exposure is prolonged, you may wish to take a third dose 1–2 hours after the second. Remember that *P.* 

## For people who want to improve their facial skin appearance

At night, apply a thin coat of a <u>retinoic acid</u> topical solution after gently washing your face with mild soap and completely patting it dry. Apply once daily, every other day, or every third day, as tolerated.

Additionally, take 320 mg of <u>cocoa flavanols</u> per day. If you see no results after 6 weeks, try 600 mg/day. To obtain these levels, consume one of the following.

- Cocoa powder (dried, unfermented): 6 to 12 g/day
- Dark chocolate (70% or higher): 25 to 50 g/day

In people with <u>acne</u> or a history of acne, chocolate (but not concentrated cocoa flavanols) may exacerbate outbreaks.

## For people with dry skin

Ensure that your core option is a moisturizer that contains a broad-spectrum <u>sunscreen</u> with an SPF of at least 30. In the morning, apply it to sun-exposed skin. If you have <u>acne</u>, select an oil-free moisturizer.

Additionally, you can apply unrefined <u>coconut oil</u> to the affected area(s) once or twice daily for at least 2 weeks. If you see no improvements after 4 weeks of daily use, consider seeking other options.

If you use a moisturizing sunscreen in the morning, you can apply unrefined coconut oil in the evening.

### For people with acne

Ensure that your core option is an oil-free sunscreen or moisturizer-sunscreen combination.

At night, apply a thin coat of a <u>retinoic acid</u> topical solution after gently washing your face with mild soap and completely patting it dry. Apply once daily, every other day, or every third day, as tolerated.

Alternatively, apply 4% <u>nicotinamide</u> gel twice daily, alone or in combination with 1% clindamycin gel. If no visible improvements are seen after 8 weeks, consider seeking other treatment options.

Do not use topical retinoids in combination with topical nicotinamide without talking to your physician or dermatologist first.

## For people seeking to reduce their skin cancer risk

In addition to using a broad-spectrum <u>sunscreen</u>, take 7.5 mg of <u>Polypodium leucotomos</u> per kilogram of body weight (3.4 mg/lb/day).

*P. leucotomos* does not have to be taken daily to benefit from its UV-protective effects. Consume one dose 24 hours prior to sun exposure and a second the day of, at least 2 hours prior to sun exposure. If your

sun exposure is prolonged, you may wish to take a third dose 1–2 hours after the second. Remember that *P. leucotomos* can help protect your skin but is *not potent enough to replace your sunscreen*.

In clinical trials, the dosage tested was 500 mg of oral nicotinamide taken twice daily with or without food.

If you are at high risk for developing non-melanoma skin cancers (NMSCs) or actinic keratoses (people with multiple prior cases of NMSCs or in chronically immunosuppressed kidney transplant recipients), nicotinamide has been tested in clinical trials as a potential preventative measure. In these trials, the dosage tested was 500 mg of oral nicotinamide taken twice daily with or without food. *Speak with your physician, dermatologist, or skin cancer specialist before beginning this treatment.* 

## For people with androgenic alopecia

Apply a 5% minoxidil formulation once or twice daily or a 2% minoxidil formulation twice daily to a dry scalp. Do not apply the formulation within one hour of washing your hair.

## For people with plaque psoriasis

Speak with your physician or dermatologist before beginning this treatment.

At night, apply a thin coat of topical <u>tazarotene</u>, covering only the psoriatic lesions, after gently washing your face with mild soap and completely patting it dry. Apply once daily, every other day, or every third day, as tolerated.

Wash your hands after applying. If you use any moisturizers, apply them 1 hour before applying tazarotene. Tazarotene commonly comes in 0.05 and 0.1% concentrations. Beginning with 0.05% may be prudent to minimize skin irritation. If the 0.05% is well tolerated, 0.1% may be used.

## **Primary Supplements**

## Sunscreen (for skin appearance & UV protection)

## What makes sunscreen a core option

Sunscreen can mitigate photoaging (i.e., sun-induced aging of the skin) and reduce the risk of skin cancer.

#### SOLAR RADIATION

Solar radiation can promote skin aging and skin cancer. Especially dangerous is the ultraviolet (UV) spectrum, whose wavelength is shorter than that of visible light but longer than that of X-rays.

#### Sun radiation wavelengths in nanometers

ULTRAVIOLET			VISIBLE	INFRARED	
UVC	UVB	UVA			
100 - 280	280 - 315	315 - 400	400 - 700	700 - 1,000,000	

- *Visible light and infrared radiation* may contribute to skin aging more than once thought, but how much more is still being researched. [4]
- *UVA* rays account for 95% of UV rays reaching Earth's surface. They're likely the main external cause of skin aging. Like UVB rays, though to a lesser extent, they can cause sunburn and DNA damage which increase the risk of skin cancer.
- *UVB* rays account for 5% of UV rays reaching Earth's surface. They're the main cause of sunburn<sup>[55]</sup> and DNA damage, and one of the main causes of skin cancer. They contribute to skin aging, though to a lesser extent than UVA rays.
- UVC rays are filtered out by Earth's atmosphere; they don't reach its surface.

UV rays hit hardest during the summer, at high elevations, and between 10 a.m. and 4 p.m. worldwide. Their effects on both cancer risk and skin aging accumulate with time, so you'll benefit from using sunscreen consistently over the years, especially if your Fitzpatrick skin type/number (see below) is low (1–3).

#### Fitzpatrick skin type scale

SKIN TYPE		WITHOUT SUNSCREEN				MED*	
		Do you		How is your skin after		MED* (mJ/cm²)	
		Burn?	Tan?	24 Hours?	7 Days?	UVA	UVB
	1	Always	Never	Painful	Untanned	20-35	15-30
	2	Readily	Minimally	Tender	Lightly tanned	30-45	25-40
	3	Moderately	Moderately	Sensitive	Moderately tanned	40-55	30-50
	4	Minimally			Deeply tanned	50-80	40-60
	5	Rarely	Easily	Unburnt	Darker	70–100	60-90
	6	Hardly ever			Unchanged	100	90-150


<sup>\*</sup> The MED (minimal erythema dose) is defined here as the least amount of UV *radiation* that causes sunburn 24–48 hours after exposure. *References:* Labban et al. *Saudi Dent J.* 2017. Eilers et al. *JAMA Dermatol.* 2013. D'Orazio et al. *Int J Mol Sci.* 2013. Heckman et al. *J Vis Exp.* 2013. Matts et al. *Br J Dermatol.* 2007. Astner and Anderson. *J Invest Dermatol.* 2004. Fitzpatrick. *Arch Dermatol.* 1988.

#### SUN PROTECTION FACTOR (SPF)

SPF is not a direct indication of how long the sunscreen will remain effective once applied. Rather, it is a measure of how well it'll protect you. [66] If your sunscreen is rated SPF 30, for instance, your skin will need 30 times more UV exposure to visibly darken (a very mild sunburn), compared with using no sunscreen. [66]

The SPF number, therefore, is inversely related to the percentage of UV radiation that penetrates your skin: SPF 15 will allow about twice as much UV radiation to reach your skin as will SPF 30 (6.67% vs. 3.33%). Importantly, no sunscreen blocks 100% of UV rays (although SPF 100 gets close in lab tests).

#### Relationship between SPF number and percentage of blocked UV rays



Adapted from Schalka and Silva dos Reis. An Bras Dermatol. 2011. [68]

This inverse relationship between UV exposure and SPF holds true only under ideal laboratory testing conditions. In the real world, it'll be influenced by a host of factors: latitude, altitude, season, time of day, reflective surfaces, sweat rate, rate of UV radiation from the sun, cloud cover, amount of sunscreen applied, reapplication frequency, how quickly the UV filters in a product start to break down, and distribution of these filters in the product and on the skin. [67][69][68]

#### CHEMICAL UV BARRIERS

Some chemicals can block UVA, UVB, or both. Technically, "sunscreen" refers to *organic* chemical barriers, whereas "sunblock" refers to *physical* chemical barriers. But the terms are commonly used interchangeably ("sunscreen" is <u>more popular</u>), and products can combine both barriers.

*Physical chemical barriers* (aka inorganic chemical barriers or mineral sunscreens) function by reflecting and dissipating UV rays. In the European Union, Canada, and the United States, the only two approved physical barriers are zinc oxide and titanium dioxide.

Organic chemical barriers function by absorbing and dissipating UV rays. They can be made with cinnamates, salicylates, benzophenones, dibenzoylmethanes, or derivatives of *para-aminobenzoic acid* (<u>PABA</u>), among other organic compounds. Approved organic barriers differ by country.

## Warnings about sunscreen

First of all, be aware that while proper and regular use of sunscreen can reduce the risk of skin cancer, it does not completely eliminate risk.

Benzophenones and dibenzoylmethanes are both potential skin allergens (may cause allergic reactions

when in contact with the skin) and photo-allergens (photo-allergens aren't inherently allergenic but can cause skin allergies when exposed to light or UV rays). [70][71] PABA is a potential skin allergen and irritant [72][73] but seldom used anymore. People with a history of skin allergies or sensitivities may want to select a product without those components, which are usually listed on labels as:

#### Benzophenones

- Oxybenzone (benzophenone-3)
- Sulisobenzone (benzophenone-4)

#### **Dibenzoylmethanes**

- 4-isopropyl-dibenzoylmethane
- 4-tert-butyl-4'-methoxydibenzoylmethane
- Avobenzone (butyl methoxydibenzoylmethane, Parsol 1789)

#### PABA and its derivatives


- 4-Aminobenzoic acid
- Padimate-O (octyl dimethyl PABA)
- Para-aminobenzoic acid

Physical barriers may be the safer choice for infants, children, and people with sensitive skin or skin conditions, such as <u>rosacea</u>, <u>dermatitis</u>, or <u>acne</u>. Water-based sunscreens might be better than oil-based sunscreens for people with acne or oily skin.

In those with high Fitzpatrick numbers (5 and 6), sunscreen will provide some additional protection against developing melanomas, but much less so than those with lower Fitzpatrick skin types. This is largely due to more heavily pigmented skin already providing a measure of natural UV protection, so we see a lower rate of melanoma in these populations. It is a myth that people of color do not get skin cancer; it's just that skin cancers in them tend to show up in different places: palms of the hands, soles of the feet, underneath finger- and toenails, inner surface of the mouth, and genitals. [77]

Sunscreen use in these populations can still provide benefits by preventing sunburns, protecting against premature skin aging, and reducing the occurrence of new freckles and wrinkles.

#### Trends in melanoma skin cancer by race/ethnicity, 2000-2016



Adapted from SEER Explorer. NIH SEER Program. Last updated April 15, 2019; accessed October 29, 2019

#### How to use sunscreen

Sunscreen is often not used optimally. [78][79][80][81] For maximal benefits, follow these four steps.


- 1. Use a broad-spectrum sunscreen.
- 2. Select an appropriate SPF.
- 3. Apply the right amount.
- 4. Reapply at least every 2 hours.

Select a broad-spectrum (UVA + UVB) sunscreen with a *sun protection factor* (SPF) of 30, at minimum, or 40 if you burn easily. Apply it 15–30 minutes before sun exposure — even on cloudy days, since clouds don't entirely block UV rays. They can even \_raise \_UVB levels on partly cloudy days. On days with clear skies, UVB rays that hit the earth's surface can be easily reflected back into space. On partly cloudy days, the clouds block their escape and reflect the rays back towards earth, creating a "ping pong" effect. [82] Reflective or light-colored surfaces can also increase UV intensity (e.g., snow, water, sand, light concrete).

#### Tip: When should I wear sunscreen?

To know if you should use sunscreen, check the <u>UV index</u> forecast <u>in your area</u>. When the UV index is 3 or higher, people with <u>Fitzpatrick skin types</u> 1 or 2 should keep unprotected sun exposure to less than 10 minutes; skin types 3 or 4, less than 15 minutes; and skin types 5 or 6, less than 30 minutes. [83][84]

If you plan to exceed these exposure limits, be sure to apply sunscreen and use extra protection as needed (e.g., hat, clothing, sunglasses, umbrella).



However high the SPF, you should reapply your sunscreen at least every 2 hours during sun exposure (more frequently if you have been swimming or sweating). If you have a <u>Fitzpatrick skin type</u> of 1 or 2, choose a sunscreen of SPF 40 or higher, as this additional protection can add up over time. [78][85][86] If you often forget to reapply sunscreen, go with an SPF of 70 or higher, as this can offer some additional protection. [78][85]

Using a higher SPF is not a substitute for reapplying every 2 hours during sun exposure. The higher SPF is intended to provide some additional protection in case you happen to forget to reapply. Some countries don't allow sunscreens to be labeled higher than SPF 50, instead opting to label them simply as "SPF 50+". Select one of these if this is the case where you live.

How well a sunscreen will protect you also depends on how much you apply. [69][78][87] At least 2 milligrams of sunscreen per square centimeter (mg/cm²) of sun-exposed skin has been recommended, [88] so use 30–90 mL (1–3 fl. oz.) total, depending on your height and amount of exposed skin. (One ounce or 30 mL is roughly the amount in one shot glass filled to the top.) When in doubt, you'll be safer applying a little too much than not enough.

Under ideal conditions, increases in the SPF protection number will proportionally decrease the amount of UV radiation that reaches your skin (as explained in the <u>Sun Protection Factor</u> section). But if you apply less than the recommended amount, this relationship falls apart under real-world conditions. Applying half of

what is needed would provide you not with 50% of the stated SPF protection but rather ≈30% or less. [89][90][91]

In the United States, sunscreens labeled "water-resistant" or "sweat-resistant" can remain effective for <u>40–80 minutes</u> of swimming or sweating (the label should specify the duration). There is no such thing as a <u>waterproof or sweatproof sunscreen</u>, and even water- and sweat-resistant sunscreens should be reapplied regularly.

A lotion or cream may ensure better coverage than a spray. If you use a spray, avoid inhaling it, applying it directly to your face (spray it on your hands and then apply to your face), or using it near an open flame. Rub it in to even out the application.

Physical barriers (zinc oxide and titanium dioxide) are more prone to leaving a white film on your skin, but this effect is greatly reduced if the formulation is micronized.

People with Fitzpatrick skin types 1–3 can benefit from additional sun-protective behaviors, such as seeking shade and wearing protective clothing (i.e., sleeves, long pants, or a hat). People with Fitzpatrick skin types 4–6 can still benefit from these additional measures, but to a lesser extent.

For days of low sun exposure (less than 2 hours total), apply a broad-spectrum sunscreen of SPF 30 or higher to areas of exposed skin. Reapplication is not necessary.

For days of high sun exposure (more than 2 hours total), apply a broad-spectrum sunscreen of SPF 30 or higher to areas of exposed skin. Reapply at least every two hours.

Store your sunscreen at room temperature, as prolonged exposure to heat can decrease its shelf life. When outdoors, keep your sunscreen out of direct sunlight. In the United States, the Food and Drug Administration (FDA) requires that all sunscreens <u>retain their stated efficacy</u> for 3 years from the date of manufacture.

#### Tip: Why don't you recommend brands or specific products?

#### For two reasons:

- We don't test physical products. What our researchers do all day, every day is analyze peer-reviewed studies on supplements and nutrition.
- We go to great lengths to protect our integrity. As you've probably noticed, we don't sell
  supplements, or even show ads from supplement companies, even though either option
  would generate a lot more money than our Supplement Guides ever will and for a lot less
  work, too.

If we recommended any brands or specific products, our integrity would be called into question, so ... we can't do it. That being said, in the interest of keeping you safe, we drew <u>a short list of steps</u> you should take if a product has caught your interest.

## **Secondary Supplements**

## Minoxidil (for hair loss)

## What makes minoxidil a primary option

Topical minoxidil is an effective way to slow, stop, or partially reverse the form of hair loss known as <u>androgenetic alopecia</u>, commonly referred to as male- or female-pattern baldness.

#### Prevalence of androgenetic alopecia

POPULATION	MALE	FEMALE
African	14.6%	3.5%
Caucasian	80.0%	40.0-50.0%
Chinese	21.3%	3.5%
Indian	58.0%	_
Korean	14.1%	5.6%

References: Dhariwala and Ravikumar. J Cosmet Dermatol. 2019. <sup>[93]</sup> ● Shankar et al. Int J Trichology. 2009. <sup>[94]</sup>

Research on topical minoxidil (sold notably under the name Rogaine®) began in the 1970s. Today, this over-the-counter medication is one of the most effective and safest treatments for androgenetic alopecia (balding) in both males and females. but people with most effective in the early stages of hair loss and in people with smaller bald patches, but people with more advanced hair loss can also benefit. Although it has mostly been studied in people with androgenetic alopecia, it may also work in people with different underlying causes of hair loss.

Hair regrowth may take a few months to become visible and up to a year to peak. [99] If you stop treatment, you will resume balding [99] and quickly lose the hair you had preserved.

Minoxidil has been tested in combination with many other therapies, including the <u>vitamin A</u> compound <u>tretinoin</u> (in isolation or in the same solution), extracts of *Curcuma aeruginosa* (in the same solution), pyrithione <u>zinc</u> (in a separate shampoo), and Korean red <u>ginseng</u> (as an oral supplement). None of these combinations have shown universally superior results over minoxidil alone, but some may be more effective in certain cases. Research is promising, but more is needed.

There is preliminary evidence that the following combinations might be superior to minoxidil alone.

- Solution: 12.5% minoxidil, 5% azelaic acid, 0.025% betamethasone valerate[106]
- Solution: 3% minoxidil, 0.25% finasteride[107]
- Microemulsion: 5% minoxidil, 0.5% diclofenac, 5% tea tree oil[108]
- 2% minoxidil solution, 2% ketoconazole shampoo, 1 mg oral finasteride[109]
- 5% minoxidil solution, microneedling[110]
- 5% minoxidil solution, microneedling, injections of platelet-rich plasma [1111]

## Warnings about minoxidil

If you are unsure what is causing your hair loss, consult a physician or physician specialist certified with the American and International Board of Hair Restoration Surgery (<u>ABHRS</u>) before using minoxidil. Do not use minoxidil if you are breastfeeding, pregnant, or planning to become pregnant. [99]

Topical minoxidil should not be confused with <u>oral minoxidil</u>, which is traditionally used to treat <u>hypertension</u> (high <u>blood pressure</u>). Topical minoxidil seldom affects blood pressure. If your scalp gets sore, itchy, inflamed, or very dry, propylene glycol (an ingredient common in minoxidil *liquid* solutions but absent from *foam* formulations) is a likely culprit, but it is \_possible \_for those symptoms to mean you are absorbing enough minoxidil to affect your blood pressure. If you experience scalp irritation, squamation (scaly skin), or <u>dermatitis</u> (a rash); get dizzy or lightheaded; or experience chest pains or irregular heartbeats, cease treatment immediately. People with cardiovascular conditions should be especially attuned to those symptoms.

When topical minoxidil is paired with the oral drug <u>cyclosporine</u> (Gengraf, Neoral, Sandimmune), used to prevent organ transplant rejection and treat rheumatoid arthritis and psoriasis, it may increase <u>hypertrichosis</u> (excessive growth of body hair).

#### How to take minoxidil

Minoxidil is readily available as 2% and 5% formulations. Twice-daily applications of a 5% solution appear to be moderately more effective than twice-daily applications of a 2% solution. People with sensitive skin may prefer a foam to a solution, as foams may be less irritating.


- If you choose a 5% formulation, apply it once or twice daily.
- If you choose a 2% formulation, apply it twice daily.

Apply the formulation to a dry scalp. Do not apply it within one hour of washing your hair. *It is critical that the minoxidil formulation reach the scalp to be effective.* For this reason, people with long hair may wish to use a solution, as a foam may not reach the scalp as easily. Additionally, some minoxidil products come with applicator tips that help ensure the formulation can get past the hair and reach the scalp.

A potential side effect of minoxidil is <u>hypertrichosis</u> (excessive growth of body hair). This is more likely to occur on your face and the back of your hands, where minoxidil accidentally gets transferred. After applying minoxidil, wash your hands and wait two hours before going to bed (to avoid transferring some minoxidil to your pillow).

Within the first 2 to 8 weeks of treatment, you may experience increased hair loss,^ ^after which your hair will begin to regrow. [99] If the hair loss persists after 8 weeks, consider consulting a general practitioner or physician specialist certified with the ABHRS, or try using the higher 5% formulation if you're using 2%. If you see no improvement (hair regrowth or reduced hair loss) after consistent use for 6 months, you may want to consider ceasing treatment and seeking other options, as you may be a minoxidil nonresponder. [99][116]

#### Hair growth cycle



Reference: Ulrike Blume-Peytavi et al. Biology of the Hair Follicle (chapter 1 in Hair Growth and Disorders. Springer, Berlin, Heidelberg. 2008. [117]

It is not uncommon for people experiencing hair loss to use a multi-treatment approach. If minoxidil does not yield the results you were hoping for, consult a general practitioner or ABHRS-certified physician about other treatment options.

Lastly, store the medicine at room temperature in a dry place and limit its exposure to heat and sunlight.

## Vitamin A (for acne & skin appearance)

## What makes retinoids a primary option

Topical retinoids are an effective treatment and preventive measure for mild to severe <u>acne</u> and mild to moderate skin photoaging (i.e., wrinkles, uneven skin pigmentation, and decreased skin elasticity accelerated by UV exposure).

Vitamin A is a catch-all term for a number of related compounds. Retinol is one of the most abundant types of vitamin A<sup>[118]</sup> and can convert into biologically active (e.g., retinal and retinoic acids) or inactive (e.g., retinyl esters<sup>[119]</sup>) forms.

Retinoids can generally be divided into four groups: retiny/ esters, retinols, retinals, and retinoic acids. The legal status of different topical retinoids varies among countries. Retinyl esters, retinol, and retinals are less potent than retinoic acids. Thus, products containing these forms are commonly available in over-the-counter products; those containing retinoic acids tend to be more regulated. For example, in the United States isotretinoin not only requires a prescription, but is also strictly regulated and tracked by the FDA.

#### Topical retinoid categories

Retinyl esters (_least potent_)	Retinols	Retinals	Retinoic acids (_most potent_)
------------------------------------	----------	----------	-----------------------------------

Retinyl esters (_least potent_)	Retinols	Retinals	Retinoic acids (_most potent_)
Retinyl acetate Retinyl linoleate Retinyl oleate Retinyl palmitate Retinyl propionate Retinyl retinoate Retinyl stearate	Retinol	Retinal Retinaldehyde	Adapalene Isotretinoin Tazarotene Tretinoin

#### **ACNE**

Topical retinoids are a first-line treatment option for inflammatory and noninflammatory mild to severe acne. [120][121][122][123] Retinoids can be used as a solo treatment but are typically used in tandem with other therapies, particularly in cases of moderate to severe acne. [120][121][122][123] As an added bonus, retinoids can also reduce acne-induced scarring and uneven skin pigmentation, which can appear on the skin as the acne lesions heal. [124]


Adapalene, isotretinoin, tazarotene, and tretinoin are the most effective retinoid treatment options. [125][126] All of these work in a dose-dependent manner, with higher concentrations having greater efficacy. [124] However, higher concentrations are prone to producing more unwanted side effects. [127] Of the retinoic acid treatments, adapalene (both 0.1 and 0.3%) is generally better tolerated, producing fewer side effects. [127][128]

There have been far fewer studies examining the effects of retinyl esters, retinol, retinal, and retinaldehyde on acne. To be more effective, these substrates must be converted into the most active form: retinoic acid. [129] While these conversions can take place when applied to the skin, much higher concentrations must be applied to achieve the same effect as a lower-concentration retinoic acid. For example, retinol has been speculated to be 10 to 20 times less effective than the retinoic acid tretinoin, and the skin concentrations of retinoic acid were 1,000-fold less than when tretinoin was applied topically. [130][131]

#### SKIN PHOTOAGING

Photoaging is primarily driven by repeated, prolonged, and unprotected exposure to UV radiation. People who are more susceptible to photoaging include smokers, males, people who receive a large amount of daily sun exposure, and people with <u>Fitzpatrick skin types</u> 1–3. People with types 4–6 generally experience a later onset of photoaging, with less severe manifestations.

#### Effects of ultraviolet A and B rays (UVA/UVB) on skin health



Reference: Krutmann et al. J Dermatol Sci. 2017.[4]

Isotretinoin, tazarotene, and tretinoin are the most well-studied topical retinoids showing the best efficacy for treating photoaged skin. Although potentially less effective, adapalene is possibly a viable treatment as well, but further studies are needed. It stills are needed.

There are fewer studies looking at the effects of retinyl esters, retinol, retinal, and retinaldehyde on photoaged skin. The retinyl esters that have been studied have not been shown to be effective. Retinol does perform better than placebo, but there is insufficient data to say if it works as well as retinoic acids (although it does show promise as a co-treatment. Retinaldehyde has shown the greatest promise as a treatment for photoaged skin, with some studies reporting effects comparable to retinoic acids, but more long-term studies are needed.

## Warnings about retinoids


High doses of oral retinoids have been linked to <u>severe birth defects</u>, and although intermittent topical retinoid use has not, there are not enough data to conclude if regular use is safe for females who are breastfeeding, pregnant, or planning to become pregnant. <u>Topical retinoids should not be used during these times.</u>

Retinoids work in a dose-dependent manner: the higher the retinoid concentration, the more effective the treatment. But these higher concentrations also increase the chances of skin irritation (e.g., dryness, redness, scaling, peeling, itching, sun sensitivity, and swelling). If any of these occur, try one or a combination of the following.

- Reduce the application frequency (switch from daily to every other or every third day).
- Reduce the amount (aim for a pea-sized dose on the forehead, each cheek, and chin).
- Apply the retinoid to the intended treatment area. After 30–60 minutes, wash it off with mild soap.
- After washing and drying your face, apply an oil-free moisturizer. Wait 20 to 30 minutes and then apply the treatment.
- Minimize unprotected sun exposure.

For all topical retinoids, skin irritation usually disappears within 2–4 weeks. Discontinue use and consult your physician or dermatologist if skin irritation is severe or persists for 6 weeks or longer.

#### Common side effects of topical retinoid applications



Most side effects were seen with extended and daily applications but were mostly mild in severity.

Even though some products, such as adapalene, are photostable (i.e., they don't degrade or cause skin irritation when exposed to UV rays), it's best to apply retinoid treatments at night to reduce the risk of skin irritation and maximize their efficacy. Daily morning application of an oil-free moisturizer may aid in reducing adverse treatment effects. An oil-free moisturizer containing broad-spectrum sunscreen with an SPF of at least 30 may provide additional benefits; those with physical sunscreening agents, such as zinc oxide or titanium dioxide, may be better tolerated.

If you are planning to use topical retinoids in combination with other topical treatments (e.g., products that contain <u>azelaic acid</u>, <u>benzoyl peroxide</u>, <u>clindamycin</u>, <u>dapsone</u>, <u>erythromycin</u>, glycolic acid, kojic acid, <u>salicylic acid</u>, sulfacetamide, or <u>vitamin C</u> (L-ascorbic acid)), discuss these options with your physician or dermatologist beforehand. Combining treatments may cause undue skin irritation or damage or alter treatment efficacy.

If you get any retinoids in your mouth, nose, or eyes, rinse thoroughly with water. If you miss a dose, do not "double up" during the next application. Continue your application schedule as usual.

People with fish allergies might want to avoid Atralin<sup>®</sup> (a micronized tretinoin gel), because it contains

#### How to take retinoids

While there have been many head-to-head trials of different retinoic acids, concentrations in these studies have varied widely. [128][145][146][147][148][149][150] So it cannot be conclusively stated that one retinoic acid treatment is entirely superior to another. It is possible that choosing an appropriate concentration is more important than the type. [144]

When deciding which retinoid product to use, go with the most potent concentration you can tolerate that produces the least skin irritation. This may take some trial-and-error testing, but a good approach is to begin with the lowest concentration of the retinoid you choose. [151] Products using "gel microspheres" or "micronized" formulations to deliver retinoids to the skin's surface are less likely to cause skin irritation. [152][153][154][155][156][157]

Retinoids can be used as a preventive treatment, so you should apply them to the entire area you intend to treat and not just as a spot treatment for individually affected segments. For example, for facial acne, apply to the entire face and not just to individual acne lesions.

It may take up to 8 weeks to see visible improvements for acne; for photoaged skin, up to 6 months.

For treating *acne*, gently wash the affected areas with mild soap and completely pat dry. Wait 20 to 30 minutes and then apply a thin coat to the treatment areas in the evening once daily, every other day, or every third day, as tolerated. Wash your hands after applying. Select one of the following retinoids:

- Adapalene (0.1-0.3%)
- Isotretinoin (0.05–0.1%)
- Tazarotene (0.05-0.1%)
- Tretinoin (0.01-0.1%)

Adapalene may be the best option to start with for people with mild to moderate acne, as it tends to be tolerated better than other retinoic acids and is commonly available over the counter. For people with more severe acne, isotretinoin, tazarotene, or tretinoin in combination with antimicrobials or antibiotics may be warranted. These combination options should be discussed with a physician or dermatologist.

Retinaldehyde topical treatments might be effective against acne, although their effects are less studied. If you opt for a retinaldehyde treatment, select a product with a high concentration (≥0.1%).

For treating *photoaged skin*, gently wash the affected areas with mild soap and completely pat dry. Wait 20 to 30 minutes and then apply a thin coat to the treatment areas in the evening once daily, every other day, or every third day, as tolerated. Wash your hands after applying. Select one of the following retinoids:

- Isotretinoin (0.05-0.1%)
- Tazarotene (0.05-0.1%)
- Tretinoin (0.025-0.1%)

Tretinoin may be the best option to start with, as it offers the lowest retinoic acid concentration and a greater variety of standardized concentrations (0.025%, 0.0375%, 0.05%, and 0.1%) if you want to try various doses. Tretinoin does come in a 0.01% concentration, but this has not been shown to be effective for photoaged skin.

Adapalene (0.1-0.3%) may also be a viable treatment option, but there is less evidence in this area, and the

effects may not be as potent as those of isotretinoin, tazarotene, or tretinoin.

Retinaldehyde topical treatments might be effective for treating photoaged skin, although their effects are less studied. If you opt for retinaldehyde, select a product with a high concentration ( $\geq$ 0.1%).

For treating both *acne and photoaged skin*, follow the application instructions above and select one of the following retinoids:

- Isotretinoin (0.05–0.1%)
- Tazarotene (0.05-0.1%)
- Tretinoin (0.025-0.1%)

## **Promising Supplements**

## **Cocoa Extract** (for skin appearance & UV protection)


## What makes cocoa extract a secondary option

Cocoa might reduce wrinkles and protect from UV rays, but it might also worsen acne.

Studies on the effects of oral and topical cocoa flavanols on facial skin have mostly been conducted in older females with pale skin (<u>Fitzpatrick skin types</u> 1 or 2).

Two randomized controlled trial (RCTs), lasting 3 and 6 months, saw small reductions in skin *roughness* and *wrinkles* from 320 mg of flavanols (from high-flavanol cocoa powder taken once a day). Two studies saw improvements in skin *elasticity* from 320–600 mg of daily flavanols (from chocolate or high-flavanol cocoa powder). Cocoa's effects on skin *hydration* are inconsistent. The effects on facial wrinkles, roughness, and elasticity can take up to 3 months to visibly manifest. Oral cocoa flavanols appear to prevent wrinkles better than they reduce existing ones.

#### Main effects of 6 months of flavanol supplementation on skin



Reference: Yoon et al. J Nutr. 2016.[158]

One 5-week study testing a topical gel with 10% cocoa flavanols saw some reduction in wrinkles by week 3 and a greater reduction by week 5 (12% overall reduction compared with placebo gel). It also reported increases in skin hydration. This study, however, has yet to be replicated.

RCTs on UV protection have used 320-600 mg of daily flavanols (from high-flavanol cocoa powder or

chocolate). The participants, almost all females with pale skin (<u>Fitzpatrick skin types</u> 2 or 3), saw a modest improvement in their skin's ability to resist UV-induced damage in as little as 6 weeks of supplementation. One trial saw no difference between the cocoa group and the placebo group, but the results may have been confounded by a placebo that contained enough flavanols to significantly raise blood levels, the cocoa group possibly getting more sun (the placebo group finished the study in the spring; the cocoa group, in late spring or early summer), and participants dropping out or not following protocol.

## Warnings about cocoa extract

Cocoa flavanols should never be used to replace sunscreen. The compounds in cocoa are not potent enough to deliver the same UV protection that a broad-spectrum <u>sunscreen</u> will.


Unfortunately, in people with acne or a history of acne, chocolate — but not concentrated cocoa flavanols — may exacerbate outbreaks. Short-term studies ( $\leq 1$  month) in people (mostly males) with mild to moderate acne noted increases in outbreaks from various single doses of 100% unsweetened cocoa powder<sup>[163]</sup> and from 1 to 12 oz of milk chocolate<sup>[164]</sup> or unsweetened dark chocolate ( $\geq 99\%$ )<sup>[165][166]</sup> per day. It has been hypothesized that the fatty acids in cocoa (cocoa butter) might be the component exacerbating acne. It is not known if chocolate can cause acne outbreaks in people not prone to them.

Cocoa flavanols may increase the risk of bleeding in people with bleeding disorders [167][168][169][170] or who take antiplatelet or anticoagulant drugs, such as aspirin or warfarin (Coumadin). Cocoa flavanols are hypotensive agents (they lower blood pressure). Taken with other hypotensive agents, which can be <a href="mailto:pharmaceuticals">pharmaceuticals</a> but also <a href="mailto:supplements">supplements</a>, such as <a href="mailto:garage">garlic</a>, they could cause episodes of low blood pressure.

Cocoa beans contain <u>caffeine</u>. There is about <u>20 mg of caffeine</u> in 25 g of dark chocolate (70–85% cocoa). If you are pregnant or breastfeeding, remember that you should <u>limit your total caffeine intake</u> to <200 mg/day. For healthy adults, caffeine intake of <u>up to 400 mg/day</u> doesn't raise any general health concerns. 1271[172][172]

Cocoa flavanols can hinder the absorption of iron — particularly non-heme iron, found in plants. [174][175][176] If you take an iron supplement, do not take cocoa flavanols at the same time.

#### Classification hierarchy of polyphenols



#### How to take cocoa extract

Start with 320 mg of cocoa flavanols per day. If you see no results after 6 weeks, try 600 mg/day. The easiest way to get your cocoa flavanols is by consuming cocoa powder or dark chocolate:

- Cocoa powder (dried and *not* fermented, roasted at high temperatures, or Dutch-style): 6–12 g/day
- Dark chocolate (70% or higher): 25-50 g/day

Cocoa powders that have *not* undergone fermentation, Dutching (alkali treatment), or roasting at high temperatures are richer in flavanols (about 60–80 mg of flavanols per gram of powder). In contrast, you would need to ingest *at least* 114 g ( $\approx$ 4 oz) of a roasted-and-fermented powder to consume 320 mg of flavanols, so you should investigate how your cocoa powder or dark chocolate was processed. In an are richer in flavanols (about 60–80 mg of flavanols per gram of powder). In contrast, you would need to ingest *at least* 114 g ( $\approx$ 4 oz) of a roasted-and-fermented powder to consume 320 mg of flavanols, so you should investigate how your cocoa powder or dark chocolate was processed.

Acticoa™ powder (≈4% flavanols)<sup>[184]</sup> and the CocoaVia® high-flavanol cocoa products were shown in company-sponsored clinical trials to reliably raise blood flavanol levels compared with low-flavanol controls.<sup>[159][162][185]</sup> The Acticoa™ powder provided 320 mg of flavanols per 8 g of powder and 600 mg per 15 g. CocoaVia powder® provided 320 mg of flavanols per 6 g of powder and 600 mg per 11 g.

Milk chocolate is too poor in flavanols for supplementation, as are cocoa nibs. In fact, you would need to ingest more than 60 g ( $\approx$ 400 kcal) of cocoa nibs to reach 320 mg of flavanols. [186]

## **Coconut Oil** (for atopic dermatitis & dry skin)

## What makes coconut oil a secondary option

Unrefined coconut oil may be a viable treatment for both atopic dermatitis and dry skin.

Two RCTs compared unrefined coconut oil with mineral oil in people with mildly to moderately dry skin. The oil was applied twice daily to the affected areas. Regardless of the oil used, all participants saw similar improvements.

For atopic dermatitis, two RCTs compared unrefined coconut oil with either mineral or virgin olive oil. In each trial, unrefined coconut oil reduced bacteria concentrations and rehydrated the skin better than the comparator, perhaps thanks to the antimicrobial properties of two saturated fatty acids present in coconut oil: lauric acid and monolaurin (a compound formed from lauric acid). [189]

These four RCTs in adults, as well as others in infants, indicate that coconut oil can be an effective general moisturizer.

## Warnings about coconut oil

For people with <u>acne</u> or oily skin, coconut oil may not be an ideal moisturizer.

### How to use coconut oil

When selecting a coconut oil, note that there is no legally-mandated definition of the terms "unrefined", "virgin", and "extra-virgin" coconut oil. Any coconut oil with one of these labels will suffice.

For *dry skin or general skin hydration*, apply unrefined coconut oil to the affected area(s) once or twice daily for at least 2 weeks. If you see no improvement after 4 weeks of daily use, consider other treatment options.

For *atopic dermatitis*, there is insufficient evidence to determine if coconut oil works as well as or better than currently available treatment options. If you wish to use it alongside other therapies, discuss this with your physician or dermatologist.

## vitamin b3 (for acne)

## What makes nicotinamide a secondary option

Nicotinamide (aka niacinamide) is a compound with anti-inflammatory properties that may be effective in treating <u>acne</u>, a chronic inflammatory skin disease.

Each vitamin has different forms, called vitamers. Nicotinamide is a B<sub>3</sub> vitamer. [194]

The 10 clinical trials conducted on nicotinamide thus far can be categorized into three groups:

- Topical nicotinamide alone vs standard-of-care treatment alone[195][196][197][198]
- Topical nicotinamide with standard-of-care treatment vs standard of care alone[1991]2001[2011]2021
- Multi-ingredient oral supplement containing nicotinamide vs standard-of-care treatment or placebo[203][204]

In the *oral* nicotinamide studies, two studies used 600 and 750 mg/day doses of nicotinamide within a multi-ingredient product; neither had a group testing nicotinamide in isolation. Thus, it is uncertain if oral nicotinamide could provide a benefit to acne treatment.

In the *topical* nicotinamide studies, the comparator group (aka standard-of-care) commonly used twice daily 1% clindamycin gel (an antibiotic), whereas the intervention groups commonly used twice daily 4% nicotinamide gel with or without clindamycin gel.

In 9 of the 10 trials, the nicotinamide groups did not perform better compared with standard-of-care acne treatment. In the lone trial that saw a benefit over standard-of-care, a 4% nicotinamide cream treatment was compared with 1% clindamycin cream for 12 weeks. The nicotinamide group saw only a slight advantage over the clindamycin group.

Across all trials, the average duration was 8 weeks, but the standard-of-care treatments being used in the comparison groups often need 12 weeks or more to produce their full benefits. So while it appears nicotinamide may be at least as effective as clindamycin, it is not known if it performs better than or enhances the effectiveness of other first-line acne treatment options currently available (i.e., benzoyl peroxide, topical retinoids), antibiotics, or combinations of these therapies).

## Warnings about *nicotinamide*

Side effects of topical nicotinamide may include mild itching, burning, <u>dermatitis</u>, or unusually oily skin. However, these side effects can also accompany topical standard-of-care treatments. If you experience these symptoms, decreasing the application frequency or amount may help until your skin adapts. If symptoms persist, cease treatment and talk to your physician or dermatologist.

Topical nicotinamide is known to have skin-lightening effects, [207] but people recovering from acne may experience skin <u>dyspigmentation</u> or <u>hyperpigmentation</u> (noticeably uneven skin tone), so in certain cases the lightening effects might be beneficial for improving aesthetics. Initial studies are promising, [208] but more research is needed.

#### How to take *nicotinamide*

For *topical nicotinamide*, apply 4% nicotinamide gel twice daily for at least 8 weeks. This can be used in combination with a 1% clindamycin gel prescription, but you should speak about this option with your physician or dermatologist.

For oral nicotinamide, there is not enough evidence to say what an effective dose might be at this time.

When taken orally at high doses, <u>vitamin B3</u> can cause an unpleasant "flushing" effect, where the blood vessels dilate, causing skin redness often accompanied by itching or burning sensations. Nicotinamide does not produce these same effects.

## <u>vitamin b3</u> (for non-melanoma skin-cancer prevention)

#### 1 Caution: An important disclaimer


The following section discusses research on nicotinamide and its effects on skin cancer incidence and recurrence. While supplemental nicotinamide is available without a prescription, *make sure to speak with your physician, dermatologist, or skin cancer specialist before beginning or modifying any cancer prevention modality.* 

## What makes nicotinamide a secondary option

Each vitamin has different forms, called vitamers. Nicotinamide, also known as niacinamide, is a  $B_3$  vitamer. Nicotinamide may reduce the incidence of new <u>non-melanoma skin cancers</u> (NMSCs) and <u>actinic keratoses</u> (AKs), which can develop into NMSCs in populations at high risk for developing them, specifically people with multiple prior cases of NMSCs or in chronically immunosuppressed kidney transplant recipients. [212][213]

Skin cancers can be roughly divided into two groups: <a href="melanoma">melanoma</a> skin cancers and NMSCs, which include squamous cell carcinomas and basal cell carcinomas. Risk for developing these skin cancers is increased with prolonged and unprotected exposure to UV radiation. Nicotinamide can help offset the negative impacts of UV damage through a number of mechanisms: [212][214]

- Accelerates DNA repair
- Reduces the degree to which UV rays suppress immune system repair functions
- Helps regulate skin inflammation and protective barrier function
- Can help restore cellular energy levels



To date, five RCTs have been conducted in this area. Four were smaller trials (24–41 participants) in high-risk populations that lasted less than 6 months. [215][216][217] They examined the effects of oral or topical nicotinamide in reducing AKs. The three studies that tested oral nicotinamide, in doses between 500 and 1,000 mg/day, all saw reductions in AKs over placebo. [215][216] The one study using topical 1% nicotinamide daily saw no noteworthy improvement over placebo. [217]

The longest and largest clinical trial was a 386-participant, 12-month RCT with a 6-month post-trial follow-up period. All participants had been diagnosed with at least 2 NMSCs (histologically confirmed) in the past 5 years and thus were at higher risk for developing further skin cancers. Subjects were randomized to receive 500 mg of nicotinamide or placebo twice daily. At the trial's end, the nicotinamide group saw a 23% reduction in new NMSCs and a 13% reduction in AKs compared with placebo. People who had entered the trial with the highest number of previous NMSCs (>6) appeared to respond most favorably to treatment. Importantly, the benefits disappeared 6 months after the treatment stopped.

When a different group of scientists analyzed this study using a different statistical method, they found nicotinamide produced no meaningful effect. However, they left the door open for future studies to corroborate the beneficial findings initially reported.

## Warnings about nicotinamide

At present, there is insufficient evidence to determine if nicotinamide could prevent or reduce NMSCs or AKs in people without a prior history of them, in lower-risk populations, or in people susceptible to developing melanomas. Additionally, more studies will be needed to determine if nicotinamide remains an effective and tolerable treatment in high-risk patients over longer periods.

Don't take niacin (aka nicotinic acid, the best-known  $B_3$  vitamer) or nicotinamide riboside instead of nicotinamide (aka niacinamide or nicotinic acid amide). When taken at high doses, niacin can cause an unpleasant "flushing" effect, where the blood vessels dilate, causing skin redness often accompanied by itching or burning sensations. Nicotinamide does not produce these same effects, allowing it to be taken at the high doses needed to elicit a therapeutic effect.

Two public health agencies have set upper limits for nicotinamide. In the European Union, the *Tolerable Upper Intake Level* (<u>UL</u>), or maximal intake deemed unlikely to pose adverse health effects in humans, is set at 900 mg/day, while the United Kingdom has set a *Safe Upper Level* (SUL) at 500 mg/day. Additionally, a recent review found that in otherwise healthy individuals, adverse effects were not seen in people consuming up to 1,000 mg/day compared with placebo. The yearlong RCT discussed above reported that adverse effects were slightly higher in the intervention group at the 1,000 mg/day dose.

While few drug interactions have been seen with nicotinamide, it might possibly interact with <u>carbamazepine</u> (Tegretol, Carbatrol, Epitol), an anticonvulsant. People with liver disease or diabetes should consult their physician before taking nicotinamide.

With the dosages suggested below, you should stop taking other forms of <u>vitamin B3</u> because the combined total intake would be more likely to place you at risk for adverse effects.

#### How to take *nicotinamide*

In clinical trials, the dosage tested was 500 mg of oral nicotinamide taken twice daily with or without food.

For topical nicotinamide, there is not enough evidence to say what an effective dose might be at this time.

## **Polypodium Leucotomos** (for UV protection)

## What makes *Polypodium leucotomos* a secondary option


Polypodium leucotomos (P. leucotomos) may help reduce the damaging effect of UV radiation on your skin.

The bioactive compounds in *P. leucotomos*, a tropical fern from Central America, can deliver UV protection to skin through multiple mechanisms. Both animal and human studies have demonstrated its ability to reduce UV-caused skin cell damage, DNA damage, and <u>oxidative stress</u>; improve immune response to UV damage; and inhibit the release of inflammatory <u>cytokine</u> proteins. [223]

Clinical trials in healthy participants have consistently shown \_P. leucotomos \_to protect the skin from UV radiation, both in short (<1 week)[224][225][226][227][228][229] and long-term (1- to 3-month) trials.[230][231][232] These UV protective effects have also been seen in clinical trials of people with skin ailments, such as polymorphous light eruptions,[232] or at high risk for melanomas.[226]

Nearly all of these studies have been conducted in people with <u>Fitzpatrick skin types</u> 1–3, which are the most susceptible to UV damage, but people with skin types 4–6 can still see benefits, to a lesser extent. Additionally, research into \_P. leucotomos \_has mostly been conducted on a proprietary extract sold notably under the brand names Heliocare® and Fernblock®.

#### Potential benefits of \_Polypodium leucotomos\_



## Warnings about P. leucotomos

*P. leucotomos should never be used to entirely replace sunscreen.* The compounds in this plant are not potent enough to deliver the same UV protection that a broad-spectrum sunscreen will. What UV protection *P. leucotomos* does deliver has an estimated SPF equivalent of  $\approx 4^{12291}$  — far below the recommended level of at least 30. Using a broad-spectrum SPF sunscreen in combination with *P. leucotomos* can provide a synergistic benefit.

The majority of clinical trials saw no adverse effects. [227][229][230][232][233][234][235] In the three trials that did, the most common complaint was gastrointestinal upset. [231][236][237] People with uneasy stomachs or health conditions affecting their intestines (e.g., IBD, IBS, celiac, Crohn's, ulcerative colitis) may wish to start with a low dose to see how it affects them.

#### How to take P. leucotomos

For *UV protection*, take 7.5 mg of *P. leucotomos* per kilogram of body weight per day (3.4 mg/lb/day). The dose can be taken all at once or split into two doses, with or without food.

Daily P. leucotomos intake by bodyweight

POUNDS	KILOGRAMS	PER DOSE (mg)	TOTAL INTAKE (mg)
100	45	170	340
125	57	215	430
150	68	255	510
175	79	295	590
200	91	340	680
225	102	380	765
250	113	425	850
275	125	470	940

The most commonly available dose is 240 mg, so get as close as you can, but don't go lower than what is recommended for your body weight.

*P. leucotomos* does not have to be taken daily to benefit from its effects. Consuming one dose at least 24 hours before sun exposure and a second dose the day of — at least 2 hours prior to sun exposure — will be sufficient to reap *P. leucotomos's* benefits.

Like sunscreen, *P. leucotomos's* protective effects will degrade over time but can be effective for up to 3 hours of sun exposure. So, if your sun exposure is prolonged, you may wish to take an additional dose right as your sun exposure begins or up to an hour after.

While some research has shown promise for *P. leucotomos* as a topical UV-protective product, there has only been one clinical trial conducted to date. Some sunscreens incorporate *P. leucotomos*, which may provide additional benefit, but to what degree is hard to say. If you buy a sunscreen with *P. leucotomos*, make sure it is in line with our sunscreen recommendations

## Tazarotene (for plaque psoriasis)

## What makes tazarotene a secondary option

In the treatment of mild-to-moderate <u>plaque psoriasis</u>, the use of the topical retinoid tazarotene alone has shown limited benefit over placebo and performed worse than other first-line treatments, such as topical <u>corticosteroids</u>, <u>vitamin D</u> analogues (<u>calcipotriene</u> and <u>calcitriol</u>), and calcineurin inhibitors (<u>tacrolimus</u> and <u>pimecrolimus</u>). Because of its high non-response rate as a solo treatment ( $\approx 73\%$ ), tazarotene might best be used in combination with other treatment options. [241]

The legal status of tazarotene varies among countries. Products containing retinoids tend to be more regulated. For example, in the United States isotretinoin not only requires a prescription, but is also strictly regulated and tracked by the FDA. Tazarotene also requires a prescription in the US.

## Warnings about tazarotene

High doses of oral retinoids have been linked to <u>severe birth defects</u>, and although intermittent \_topical retinoid use has not, there are not enough data to conclude if regular use is safe for females who are breastfeeding, pregnant, or planning to become pregnant. Topical retinoids should not be used during these times.

Retinoids work in a dose-dependent manner: the higher the retinoid concentration, the more effective the treatment. However, these higher concentrations also increase the chances of experiencing skin irritation (e.g., dryness, redness, scaling or peeling, itching, sun sensitivity, and swelling). If any of these occur, try one or a combination of the following.

- Reduce the application frequency (switch from daily to every other or every third day).
- Reduce the application amount (aim for a pea-sized dose).
- After washing and drying your face, apply an oil-free moisturizer. Wait 60 minutes and then apply the treatment.
- Minimize unprotected sun exposure.

Skin irritation usually disappears within 2–4 weeks. Discontinue use and consult your physician or dermatologist if skin irritation is severe or persists for 6 weeks or more.

Regular daily use of an oil-free moisturizer containing broad-spectrum sunscreen with an SPF of at least 30 may aid in reducing adverse effects. SPF moisturizers containing physical sunscreening agents, such as zinc oxide or titanium dioxide, may be better tolerated as chemical sunscreening agents can cause irritations in those with sensitive skin conditions.<sup>[74]</sup>

If you are planning to use topical retinoids in combination with other topical treatments (e.g., corticosteroids and vitamin D analogues), discuss these options with your physician or dermatologist beforehand. Combining treatments may cause undue skin irritation or damage, or alter treatment efficacy.

If you get any retinoid in your mouth, nose, or eyes, rinse thoroughly with water.

If you miss a dose, do not "double-up" during the next application. Continue your application schedule as usual.

#### Tip: Skincare and household products for sensitive skin

The <u>National Psoriasis Foundation</u> maintains a <u>Seal of Recognition</u> for non-irritating products created for those with psoriasis, sensitive skin, or joint mobility limitations. You can learn about the review process these products undergo <u>here</u> or browse their database of approved products <u>here</u>.

### How to take tazarotene

For *plaque psoriasis*, gently wash the affected areas with mild soap and completely pat dry. Then apply a thin coat of tazarotene, covering only the psoriatic lesions, in the evening. Apply once daily, every other day, or every third day, as tolerated, to the affected areas. Wash your hands after applying. If you use any moisturizers, apply them 1 hour before applying tazarotene.

Tazarotene commonly comes in 0.05 and 0.1% concentrations. Beginning with the 0.05% concentration may be prudent to minimize skin irritation. If the 0.05% is well-tolerated, 0.1% may be used.

## **Unproven Supplements**


# <u>Astaxanthin</u> (for skin appearance & UV protection)

### What makes astaxanthin an unproven option

Astaxanthin is a powerful antioxidant. Being fat soluble, it accumulates in the skin and other body tissues. It can reduce <u>oxidative stress</u> (a cause of <u>lipid degradation</u> and DNA damage) in human skin damaged by UVA radiation. [242][243]

Taken orally or applied topically, astaxanthin might reduce wrinkles, improve the skin's elasticity and moisture content, and protect against UV radiation. However, the clinical research isn't extensive or particularly high in quality. [242][244][245][246] More and better human studies are required for astaxanthin to become more than an unproven option.

#### Properties of smooth vs wrinkled skin



## **Caffeine** (for cellulite & skin disorders)

## What makes caffeine an unproven option

<u>Cellulite</u> is the fatty deposits that visibly collect below the skin's surface. Its development involves many components: blood vessel microcirculation, <u>lymphatic systems</u>, excess body fat, and the <u>extracellular matrix of cells</u>. When applied topically, caffeine can penetrate and accumulate in the skin, where it may

be able to inhibit some cellular signaling pathways that contribute to cellulite formation.[248]

Evidence from cell and animal models suggests that it can increase lymphatic drainage in fatty tissues, removing by-products of fatty-acid breakdown that might hinder blood vessel microcirculation. Studies using human hair follicles suggest that it might stimulate hair growth, and rodent evidence suggests that its antioxidant activity may prevent damage from UVB radiation.

However, human research on caffeine's cosmetic use is scarce and weak. In a preliminary, uncontrolled, and potentially confounded trial, the participants reported a decrease in cellulite and an increase in elasticity and moisture when asked. But this *subjective* evaluation was not supported by the *objective* clinical evaluation, which found only a minor increase in elasticity and moisture when directly measured. [252]

There is also one study on psoriasis<sup>[253]</sup> and another on <u>atopic dermatitis</u>, both of which show improvement, but they only provide us with preliminary evidence. A small number of clinical trials have tested caffeine-containing shampoos in balding males diagnosed with androgenetic alopecia. The results indicate it *might* work better than placebo, but the vast majority of these trials did not test caffeine in isolation. Thus far, evidence on the effects of topical caffeine are too weak to say if it could provide benefits for skin or hair.


## **Coconut Oil** (for hair appearance)

### What makes coconut oil an unproven option

Coconut oil has a unique combination of relatively short molecular chains, which enables it to penetrate hair fibers, protecting them from external damage<sup>[256][257][258]</sup> and helping them retain moisture more than mineral oil does.<sup>[259]</sup> However, only one human study has tested its effects on hair.<sup>[260]</sup> In this 16-week study, daily application of coconut oil prior to shampooing increased hair strength by 41.8%.

While initial evidence suggests that coconut oil can improve hair quality, more human and comparator studies are required for confirmation.

#### Hair follicle anatomy



Reference: Ulrike Blume-Peytavi et al. <u>Biology of the Hair Follicle</u> (chapter 1 in Hair Growth and Disorders. Springer, Berlin, Heidelberg. 2008.)[117]

## **Creatine** (for skin appearance)

## What makes creatine an unproven option

Collagen is a structural protein in connective tissues, such as skin, ligaments, and tendons. It degrades as you age, causing wrinkles as skin loses its elasticity. Studies in human skin cells have shown that topical creatine can be absorbed by the skin and stimulate collagen synthesis, [261][262] and human trials have seen improvements in skin appearance from creatine-containing multi-ingredient facial creams. [261][262] Creatine

alone has never been tested, however, so its effects (if any) are uncertain.

One study using oral creatine (20 g/day for 7 days) saw improvements in microvascular function and skin capillary density, which may benefit skin health, but no practical applications can be drawn from this very preliminary association.

## Forti5<sup>®</sup> (for hair loss)

## What makes Forti5 an unproven option

Forti5 is a brand-name oral supplement containing a blend of green tea leaf extract, omega-3 and omega-6 fatty acids, vitamin D<sub>3</sub>, beta-sitosterol, melatonin, and soy isoflavone seed extract.

To date, only a single study has been published testing the safety and efficacy of this supplement. It was a single-blinded pilot case series that tested Forti5 on 10 adult subjects with androgenetic alopecia. All subjects took two tablets per day for 24 weeks (≈6 months).

These very preliminary results indicated Forti5 might be able to provide slight to moderate improvements in hair density.

## Marine Proteins (for hair loss)

## What makes *marine proteins* an unproven option

Interest in the use of marine proteins for improving hair quality were first noted in early double-blind studies investigating their application for repairing sun-damaged skin in females. Since then, nearly all research has focused on AminoMar™, a proprietary blend of shark cartilage and mollusk powder, which is sold in the brand-name supplement Viviscal®. It should be noted that nearly all of the studies conducted on AminoMar and Viviscal were funded by the company that sells the product, Lifes2Good Inc.

However, there are some substantial limitations to consider.


• Studies on these marine protein blends stretch back to the early '90s, and the composition and dose of the tested blends across studies have varied quite a bit.

- AminoMar is a proprietary blend of shark cartilage and mollusk powder. While we know how much of the *total* blend is in a single tablet of Viviscal (currently ≈450 mg), we do not know the *specific* amount of either component. The amounts may have changed from study to study.
- Many secondary ingredients have been included in the Viviscal product when being tested, limiting our ability to say what effect AminoMar might have in isolation. Niacin, vitamin C, Vitamin B<sub>7</sub>
   (biotin), calcium, iron, zinc, horsetail stem extract, millet seed extract, flaxseed extract, procyanidin B-2 (apple extract powder), L-cystine, and L-methionine have all been included in Viviscal at one time or another.
- The types and amounts of secondary ingredients included have changed from study to study, sometimes in unknown ways, making it difficult to compare study results head-to-head.

Furthermore, the ingredients included in Viviscal (the AminoMar complex and various vitamins, minerals, and plant extracts) are subject to change at the desire of the company without warning, and customers may or may not be notified of these changes. Such alterations can change the product's efficacy in unknown ways.

It is possible that certain marine proteins, in isolation, may improve hair regrowth and quality. To date, there are not enough studies to say if this might be the case.

#### **Common patterns of hair loss**



For people who still want to try Viviscal, note that in the studies that reported adverse effects, no consistent ones were seen in participants taking Viviscal. [267][271][272][273][274][275][276][277] People with an intolerance or allergy to fish, seafood, shellfish, or acerola should not take Viviscal. Changes in the Viviscal formulation can affect the safety of this product on an individual level, so be vigilant about looking for any alterations.

# Minoxidil (for nail growth & non-androgenic hair loss)

## What makes minoxidil an unproven option

In a single clinical trial, participants applied a 5% topical minoxidil solution twice daily to some of their fingernails. [280] Compared with the untreated nails, minoxidil was able to increase the rate of nail growth by an average of 0.36 mm (0.014 inches) per month — a 9.2% increase over the control nails. Additional studies are needed to confirm these findings.

While minoxidil has been shown to be effective in treating androgenic alopecia, its role in treating other forms of alopecia is less certain. Studies testing minoxidil for the treatment of alopecia areata and scarring alopecias have yielded uncertain results. Some evidence indicates minoxidil might be useful for treating temporary hair loss (telogen effluvium), monilethrix, early traction alopecia, chemotherapy-induced alopecia, and eyebrow hypotrichosis, but further investigations are needed. [281]

# <u>vitamin b3</u> (for skin appearance & disorders)

## What makes nicotinamide an unproven option

Each vitamin has different forms, called vitamers. Nicotinamide, also known as niacinamide, is a  $B_3$  vitamer. In studies, it has shown promise as a solo or adjunct treatment for a number of skin conditions: wrinkles, [282][283] melasma, [284] hyperpigmentation, [207][208][283] psoriasis, [285] atopic dermatitis, [286] and bullous dermatoses. [287][288][289][290][291] On the flip side, a single RCT on uremic pruritus (caused by kidney failure) showed no difference between nicotinamide and placebo. [292]

There is currently too little evidence to determine effective dosages for any of the aforementioned conditions.

## Nutrafol<sup>®</sup> (for hair loss)

## What makes Nutrafol an unproven option

Nutrafol® is a brand-name oral supplement containing some 23 ingredients, including vitamins <u>vitamin A</u>, <u>vitamin D</u>, and <u>vitamin E</u>, <u>ashwagandha</u>, <u>curcumin</u>, <u>saw palmetto</u>, keratin, and hydrolyzed <u>marine collagen</u>, among other vitamin, mineral, and spice or herb.

To date, four case studies and two randomized, double-blind, placebo-controlled studies testing this supplement formula have been published. [293][294][295]

The first RCT was a 6-month trial that enrolled 40 females with thinning hair, 26 of whom were randomized to take four Nutrafol® pills per day while the remainder took placebo pills. At the study's end, women taking Nutrafol® experienced improvements in both hair growth and quality compared with the control group.

The second RCT reported the six-month interim results of a 12-month trial. Sixty women, 40–65 years old, with self-perceived thinning hair, were randomized to consume either a placebo or four Nutrafol pills per day. Similar to the first RCT, the women in this study also saw significant improvements in hair growth and quality. The final 12-month results of this study are not yet published.

It is difficult to compare the results of the two trials, as the type and amounts of ingredients changed in the Nutrafol® formulation between the first and second RCT. Additionally, both formulations used proprietary blends, so the exact amounts of some of the included ingredients are unknown. These results will need to be replicated in future trials before any confident conclusions about its effectiveness or drawbacks can be made.

Of note is that one of the authors on both RCTs is a researcher for the company that created the product, Nutraceutical Wellness Inc. Nutraceutical Wellness Inc. also provided funding for both studies.

# <u>Polypodium Leucotomos</u> (for skin disorders)

## What makes *Polypodium leucotomos* an unproven option

Polypodium leucotomos has been studied as a potential treatment for people at high risk for developing melanoma, and for reducing polymorphous light eruptions (the most common sun-induced dermatitis condition). [232][237][296] It's also been studied as an adjunct treatment for actinic keratoses, pigmentation disorders (vitiligo, melasma), [233][234][236][297][298][299] psoriasis, [300] and atopic dermatitis [235][301] and for preventing premature skin aging. [302][303][304] While it shows promise in many of the aforementioned domains, more clinical evidence is needed.

# <u>Probiotics</u> (for acne, eczema, & dermatitis)

### What makes probiotics an unproven option

Various probiotic strains and combinations, taken orally or applied topically, have shown promise in helping treat <u>acne</u>, <u>eczema</u>, and <u>atopic dermatitis</u>. Despite a few human trials, the data are too limited and/or conflicting to suggest which probiotics to use, how long they should be used for, and at what dosage. [3051[306]

## vitamin a (for hair loss & rosacea)

## What makes retinoids an unproven option

#### HAIR GROWTH

Topical tretinoin has not been well studied for the promotion of hair growth. One unblinded, non-randomized trial compared minoxidil 0.5%, tretinoin 0.025%, minoxidil 0.5% with tretinoin 0.025%, and placebo in 56 subjects for 12 months. Oddly, the tretinoin and minoxidil + tretinoin groups saw improvement, but the minoxidil alone group saw none. This calls into question how compliant the groups were with their prescribed treatment, or possibly the minoxidil alone group had a larger number of non-responders.

The second study was an RCT of 31 males using minoxidil 5% twice daily or minoxidil 5% with tretinoin 0.01% once daily for 18 weeks. The minoxidil + tretinoin group saw a small increase in hair growth over the minoxidil group alone. Further high-quality studies are needed to assess these initial results.

#### **ROSACEA**

There is mixed evidence on the effects of retinoid creams for the treatment of <u>rosacea</u>. In subtype II rosacea patients (those with papules/pustules), a single trial showed promise for the retinoid adapalene, but two trials have shown conflicting evidence for tretinoin. Present guidelines for the treatment of subtype II rosacea have cautiously endorsed the use of topical retinoids but stress that, given their irritative properties, their inclusion as a treatment option should be assessed on a case-by-case basis.

# Rosmarinic Acid and Grapefruit Extract (for skin appearance & UV protection)

What makes rosemary and grapefruit an

### unproven option


Photoaging and sunburns are both caused, in part, by inflammation and the formation of reactive oxygen species, a type of free radical, in the skin after <u>UV light exposure</u>. So it seems reasonable to hypothesize that antioxidants, such as those found in plant extracts, could help protect against damage caused by UV radiation.

An early study reported synergistic effects of a combination of rosemary and grapefruit extracts (NutroxSun®) in a skin cell model, showing a decrease in free radicals and reduced DNA damage after exposure to UVB radiation. The same study included a small pilot trial in 10 humans taking a 250 mg dose of the combo and showed it was able to increase the dose of UV radiation necessary to cause a sunburn, which indicates greater UV protection.

A follow-up study was conducted to build on those results by using a larger test population (90 participants) and different doses of the extract combination (100 mg, 250 mg, or placebo) over 2 months. [314] In addition to UV protective effects, this study looked at the effects on wrinkles, skin elasticity, and markers of oxidative stress.

The results showed that the extract was able to increase UV tolerance by 28%; postexposure levels of oxidative stress markers in the skin were reduced; and wrinkle depth and skin elasticity both improved. The only measure where the 250 mg dose outperformed the 100 mg dose was in the oxidative stress markers, where the higher dose saw greater reductions.

## Effects of a rosemary-grapefruit extract on UV tolerance and wrinkle depth



Reference: Nobile et al. Food Nutr Res. 2016.[314]

Despite these two promising human trials, the data are currently too limited to draw any firm conclusions about the potential benefits or drawbacks of this supplement combination.

## Vitamin B<sub>7</sub> (biotin) (for hair & nail appearance)

### What makes biotin an unproven supplement

#### **L** Caution: Biotin can affect laboratory results

Biotin can interfere with many laboratory tests, from hormone tests to cardiovascular diagnostics. Stop taking the supplement 3 to 7 days before getting any lab work done.

Biotin, also known as vitamin B<sub>7</sub>, plays a part in the production of keratin, the protein at the core of hair and nails. For that reason, it is highly popular as a supplement to improve the appearance of hair and nails. [315][316]

As it stands, no RCTs have tested biotin's effects on the hair or nails of healthy people, [317] but supplementation may promote healthy hair and nails in people with the following conditions:

- Biotin deficiency (which is rare, though maybe less so in people experiencing hair loss)[317][318]
- · Genetic disorders affecting biotin metabolism (leading to a deficiency in two enzymes responsible for processing biotin: biotinidase and holocarboxylase synthetase)[317][319]
- Some medical nail conditions (brittle nails, triangular worn-down nails, trachyonychia, and habit-tic deformity)[320][321][322][323][324][325]
- Uncombable hair syndrome [315][326][327]
- Medication-induced hair loss (caused by valproic acid, for example)[328][329][330]

The studies on biotin supplementation for the above conditions are mostly case studies that provide preliminary, though encouraging, data. People who are biotin deficient or have inborn errors of biotin metabolism are most likely to benefit from supplementation.


In cases of genetic disorders affecting biotin metabolism, larger biotin doses (10-30 mg/day) have helped. [317] If you have one of these genetic disorders, speak with your physician before starting this supplement.

In cases of biotin deficiency or medical conditions (brittle nails, uncombable hair syndrome, etc.), 0.3-3 mg/day may be beneficial.[317]

#### **Biotin and hair growth**

If you are not biotindeficient, there is no evidence that supplemental biotin can improve hair growth or quality.

Biotin deficiency can cause alopecia. When biotin levels are restored to normal, hair loss will revert.



## Vitamin E (for skin, hair, & nails)

## What makes vitamin E an unproven option

Vitamin E is a catchall term for the two main vitamin E groups, tocopherols and tocotrienols. These groups can further be broken down into subgroups that contain many different forms, not to mention there are synthetic forms as well. The specific type being used can greatly influence how the vitamin performs for a given health endpoint.

This is one of the reasons vitamin E remains an unproven option: many studies looking at the same outcome often use different forms, concentrations, and doses, making it difficult to draw any conclusions. Furthermore, there is a lack of dose-response studies using the same vitamin E form to help ascertain an optimal dose.

#### ATOPIC DERMATITIS

Only a few trials have investigated the use of oral vitamin E, either alone or in combination with other vitamins or minerals. [331][332][333][334][335] The trials are of mixed quality and provided mixed results. The data are too preliminary to include vitamin E as an atopic dermatitis treatment option. [336]

#### HAIR GROWTH

Only three clinical trials have been conducted examining a vitamin E and hair growth connection. [337][338][339] Of these, only one tested vitamin E in isolation. [337] The other two used differing multi-ingredient supplement blends that contain vitamin E. [338][339] The data are presently too limited to draw any conclusions.

#### NAIL HEALTH

Case studies and a few clinical trials have reported a benefit in nail quality with either topical or oral vitamin E in people with <u>yellow nail syndrome</u>. However, the largest double-blind RCT to date reported no benefit with topical vitamin E applications over 6 months.

Topical vitamin E might play a role in treating <u>brittle nails</u>, but much more clinical data are needed in this area. [344]

#### **UV PROTECTION**

There is strong mechanistic evidence from animal and cell studies that topical or oral vitamin E can reduce UV damage. Studies of topical vitamin E conducted in humans have provided mixed, but promising, results. [347][348][349][350][351]

Studies of oral vitamin E for UV protection have also provided mixed results. [352][353][354][355][356] To complicate matters, oral vitamin E is rarely studied in isolation. The multi-ingredient formulas tested, which contain vitamin E, are seldom replicated in additional trials. Because of these limitations, no firm conclusions can be drawn at this time.

#### WOUND AND SCAR HEALING

Vitamin E has been tested in six RCTs as a treatment for postsurgical wound and scar healing, as a solo or combination topical therapy. Three RCTs reported a meaningful improvement with using vitamin E alone, vitamin E with silicone gel sheets, and vitamin E with hydrocortisone and silicone sheets. All three of these studies used subjective measures (visual inspection or questionnaire) to assess wound and scar healing progress. These trials were all single-blinded or not blinded at all, which can limit our confidence in their results, but the combined sample size included 538 participants.

The other three RCTs reported no meaningful improvements with the use of topical vitamin E as a solo therapy. [359][360][361] These trials included the only study to use an objective assessment (direct measurement) of wound and scar healing, [361] which can help decrease bias and increase our confidence in the results. Additionally, all trials were double-blinded and had a combined sample size of 211 participants.

To complicate matters further, each of the six RCTs used differing vitamin E concentrations, so there is insufficient evidence to determine what effects vitamin E could have on wound and scar management.

## Vitamin K (for skin appearance)

## What makes vitamin K an unproven option

One study has evaluated vitamin K skin cream for reducing wrinkles and dark under-eye circles and suggested an improvement, but the methodological limitations and overall lack of research prevent any clear conclusions.[362]

More research is needed to explore the proposed mechanisms and evaluate other disorders and parameters of skin health, so vitamin K is an unproven option for skin-related areas of health at this time.

#### **PURPURA**

Fat-soluble vitamins (A, D, E, K) tend to accumulate in the skin, and vitamin K may help vitamin A improve skin vascularity (i.e., increase vein density). A cream containing vitamin K has been tested in a handful of studies for its ability to reduce <u>purpura</u> (purple- or red-colored spots) caused by laser skin therapy and <u>acneiform rashes</u> caused by the cancer drug <u>cetuximab</u>. [363][364][365][366][367][368] The results of these studies don't provide compelling evidence for a notable clinical benefit.

## **Zinc** (for acne & eczema)

## What makes zinc an unproven option

#### **ACNE**

Zinc, via its effects on the immune system, might aid in preventing mild-to-moderate <u>acne</u> by reducing skin inflammation and acne-causing bacteria. Overall, the clinical research on zinc for acne treatment suggests a benefit when taken at very high doses of 100+ mg per day over a period of 2 months or more. Contrast this with the daily *Tolerable Upper Intake Level* (UL) for adults in the US of 40 mg per day. These high doses are unsustainable, as they can cause many adverse effects.

Over time, high doses of zinc can irritate the gastrointestinal tract. They can also cause a copper deficiency, since zinc kick-starts the process of creating metallothionein, a protein that binds with zinc but also with other metals, notably copper; the bound metals then leave the body as waste products. Even higher doses of zinc can damage the liver and kidneys. Temporary adverse effects include cramping, diarrhea, nausea, vomiting, headache, or dizziness.

It is unclear if a lower, more sustainable zinc dose ( $\leq$ 50 mg/day) would be as effective as the higher doses or if zinc works as well as or better than currently available acne treatment options. It is possible zinc could be used in tandem with other treatments, but more studies are needed in this research area.

#### **ECZEMA**

Zinc, orally or topically, has also been studied for various skin conditions, such as eczema, rosacea, and psoriasis, but evidence for its use in these cases is inconsistent and sparse. [374][375][376][377][378][379][380]

## **Inadvisable Supplements**

## **Coconut Oil** (for UV protection)

### What makes coconut oil an inadvisable option

Coconut oil alone should never be used to replace sunscreen. While it may be used as an ingredient in some sunscreens, coconut oil by itself has shown an exceptionally poor ability to protect your skin from UV rays. [381] Its estimated SPF rating across the UVA and UVB spectrums is  $\leq 1$ . [381]

## PABA (for UV protection)

### What makes PABA an inadvisable option

<u>Para-aminobenzoic acid</u> (PABA), sometimes referred to as vitamin  $B_x$ , is related to vitamin  $B_9$  but is not a vitamin itself. It can be found in different foods, such as grains, eggs, livers, kidneys, and milk. Supplemental doses may darken graying hair, [382][383][384] but studies are scarce, are old, and show inconsistent results.

PABA's UVB-absorbing properties made it <u>one of the first</u> ingredients used in <u>sunscreens</u>, particularly in the 1950s and 1960s. A study on UV-induced hair damage and discoloration also found topical PABA to offer some protection, though less than topical benzophenones do.[385]

Alas, PABA is a potential skin allergen and irritant [72][73] (as are benzophenones). Since more effective ingredients are now available for UV protection — avobenzone, zinc oxide, titanium dioxide — sunscreens containing PABA are better avoided.

## Proprietary Blends and Multi-Ingredient Products

There are many brand-name products with custom supplement blends that claim to aid in hair growth or make bold claims about how they can improve your skin or nail health. The common hypothesis among these blends is that they can combine various ingredients that can act on different metabolic pathways to halt, reverse, or improve whatever condition you're trying to treat.

There is usually precious little human evidence to support the efficacy of these products. Studies are typically small, short-term, and not often replicated (even when replicated they seldom draw the same conclusions).

Be wary of these products and the claims that they make.

## **FAQ**

## Q. What about supplements not covered in this guide?

Our guides are regularly updated, often with new supplements. We prioritize assessing (and reassessing) the most popular of them and those most likely to work. However, if there is a specific supplement you'd like to see covered in a future update, please let us know by <u>filling out this survey</u>.

## Q. Can I add a supplement not covered in this guide to my combo?

Supplement with your current combo for a few weeks before attempting any change. Talk to your physician and <u>research each potential addition</u>. Check for known negative interactions with other supplements and pharmaceuticals in your current combo, but also for synergies. If two supplements are synergistic or additive in their effects, you might want to use lower doses of each.

## Q. Can I modify the recommended doses?

If a supplement has a recommended dose range, stay within that range. If a supplement has a precise recommended dose, stay within 10% of that dose. Taking more than recommended could be counterproductive or even dangerous. Taking less could render the supplement ineffective, yet starting with half the regular dose could be prudent — especially if you know you tend to react strongly to supplements or pharmaceuticals.

## Q. At what time should I take my supplements?

The answer is provided in the "How to take" section of a supplement entry whenever the evidence permits. Too often, however, the evidence is either mixed or absent. Starting with half the regular dose can help minimize the harm a supplement may cause when taken during the day (e.g., <u>fatigue</u>) or in the evening (e.g., <u>insomnia</u>).

## Q. Should I take my supplements with or without food?

The answer is provided in the "How to take" section of a supplement entry whenever the evidence permits. Too often, however, the evidence is either mixed or absent. Besides, a supplement's digestion, absorption, and metabolism can be affected differently by different foods. Fat-soluble vitamins ( $\underline{A}$ ,  $\underline{D}$ ,  $\underline{E}$ ,  $\underline{K}$ ), for instance, are better absorbed with a small meal containing fat than with a large meal containing little to no fat.

### Q. What are DRI, RDA, AI, and UL?

The <u>Dietary Reference Intakes</u> (DRIs) is a system of nutrition recommendations designed by the Institute of Medicine (a US institution now known as the <u>Health and Medicine Division</u>). RDA, AI, and UL are part of this system.

- Contrary to what the name suggests, a Recommended Dietary Allowance (RDA) doesn't represent
  an ideal amount; it represents the minimum you need in order to avoid deficiency-related health
  issues. More precisely, it represents an amount just large enough to meet the minimum requirements
  of 97.5% of healthy males and females over all ages which implies that the RDA is too low for
  2.5% of healthy people.
- The Adequate Intake (AI) is like the RDA, except that the number is more uncertain.
- The *Tolerable Upper Intake Level* (UL) is the maximum safe amount. More precisely, it is the maximum daily amount deemed to be safe for 97.5% of healthy males and females over all ages which implies that the UL is too high for 2.5% of healthy people.

As a general rule, a healthy diet should include at least the RDA of each nutrient — but less than this nutrient's UL. This rule has many exceptions, though. For instance, people who sweat more need more salt (i.e., sodium), whereas people who take <u>metformin</u> (a diabetes medicine) need more <u>vitamin B12</u>.

Moreover, the DRIs are based on the median weight of <u>adults</u> and <u>children</u> in the United States. Everything else being equal (notably age, sex, and percentage of body fat), you likely need a lesser amount of nutrients if you weigh less, and vice versa if you weigh more. The numbers, however, are not proportional — if only because the brains of two people of very different weights have very similar needs. So you can't just double your RDIs for each nutrient if you weigh twice as much as the median adult of your age and sex (even if we overlook that people weighing the same can differ in many respects, notably body fat).


## Q. Will sunscreen decrease my vitamin D levels?

Your body can produce <u>vitamin D</u> when the skin is exposed to UVB rays, [386] so it stands to reason that sunscreen use may decrease vitamin D levels. Indeed, sunscreen can cause a drop in vitamin D production under laboratory testing conditions, [387][87] and this decrease is most notable if sunscreen is used consistently and properly (i.e., when using a broad-spectrum sunscreen and the right SPF, amount, and reapplication schedule). But even then, it appears most need not worry about the effects of sunscreen alone on vitamin D levels. [390]

One important caveat — studies to date have generally been conducted on people with less skin pigmentation (i.e., those with <u>Fitzpatrick skin types</u> 1–3). A different result may be seen in those with Fitzpatrick skin types 4–6.

Generally speaking, 5 to 30 minutes of unprotected sun exposure to the hands, face, and arms at least three times a week between 11 a.m. and 3 p.m. may generally be enough to keep vitamin D levels <u>out of the deficient range</u> (<30 nmol/L or <12 ng/mL).[391][392] When the <u>UV index</u> in your area is 3 or higher, people with Fitzpatrick skin types 1 or 2 should keep unprotected sun exposure to less than 10 minutes; skin types 3 or 4, less than 15 minutes; and skin types 5 or 6, less than 30 minutes.[83][84] You can check out the UV index forecast in your area <u>here</u>.

Keep in mind that longer periods of unprotected sun exposure will not necessarily lead to higher vitamin D production, as the UVB rays will eventually degrade vitamin D in your skin to an inactive state. This actually helps protect your body against vitamin D toxicity. Additionally, UVB-induced vitamin D production can be influenced by many other factors, including:



For these reasons, it is not advisable to completely forgo sunscreen to increase vitamin D levels or rely on sun exposure as your *main* source of vitamin D. Rather, a more balanced approach would be to increase vitamin D through diet and supplementation, with some limited unprotected sun exposure added in.

#### Tip: Calculate your safe UV exposure for a healthy vitamin D status

How much UV exposure you need to maximize your body's vitamin D production depends on a number of factors: time of year, location, skin type, weather conditions, and more. Fortunately, the Norwegian Institute for Air Research has developed a calculator, based on peer-reviewed research, [395][396][397][398] that takes these factors and more into account. This tool allows you to calculate UV exposure times to obtain optimal vitamin D synthesis without burning your skin.

You can try the easier simplified model or the more complex full model.

## Q. Why don't you mention the hair loss treatment finasteride (Propecia)?

This guide is a supplement guide. We sometimes include over-the-counter medications (such as topical minoxidil), but if you need prescription medication (such as <u>finasteride</u>), please consult a physician or physician specialist certified with the American Board of Hair Restoration Surgery (ABHRS).

## Q. Why aren't there more supplements for nails?

While the market abounds in "hair and nails" products, reliable studies on nails are scarce. Benefits to nails from supplements are most often anecdotal or inferred from studies on hair.

Preliminary evidence suggests that  $\underline{\text{minoxidil}}$  might help with nail growth; vitamin B<sub>7</sub> ( $\underline{\text{biotin}}$ ) might help with brittle nails, triangular worn-down nails, trachyonychia, or habit-tic deformity; and  $\underline{\text{vitamin E}}$  might help with yellow nail syndrome and brittle nails.

Current evidence suggests that supplementation with <u>calcium</u>, <u>copper</u>, <u>iron</u>, <u>selenium</u>, <u>silic</u>, <u>zinc</u>, <u>vitamin A</u> (<u>retinoids</u>), <u>vitamin B12</u>, or <u>vitamin C</u> doesn't improve nail health or appearance in non-deficient people. [399][400]


## Q. Can I create my own sunscreen using natural plant oils?

In short, not really. When tested for protection against UVB radiation only, many plant oils provide an SPF of <8. These oils can be incorporated into commercial sunscreen products to help the overall SPF rating, but on their own they are insufficient for UV protection.

Be aware that some of these plant oils can be potentially allergenic and may cause skin irritation (such as dermatitis) in some. [402][403]

Sunscreens are formulated using specific ingredients in specific amounts in addition to employing manufacturing methods to help ensure these UV-protective ingredients are evenly distributed throughout the sunscreen. This process is very difficult to replicate at home.

#### Sun protection factor (SPF) values of plant oils



Adapted from Kaur and Saraf. Pharmacognosy Res. 2010. [401]

## Q. Do the "natural" and "clean" labels on skin care products mean anything?

The skin care market is huge, generating \$5.6 billion in sales in 2018 alone and "natural" brands were the top contributors to <u>market growth</u>. The explosive growth in the natural skin care market is driven by the desire of consumers to use products that are both safe and nontoxic.

Yet in the US, the terms "clean" and "natural" are not defined or regulated when it comes to skin care products. The inclusion of these terms on the label does not offer any assurances that the product is safer for consumers compared with products that don't contain these labels.

However, there are two natural sunscreen ingredients that have a proven track record — zinc oxide and titanium dioxide. Often referred to as physical chemical barriers (aka inorganic chemical barriers or mineral sunscreens), these naturally occurring compounds function by reflecting and dissipating UV rays.


## Q. Will creatine cause hair loss?

The idea that creatine *might* increase hair loss stems from a single randomized controlled trial (RCT) whose participants (20 healthy, young, male rugby players) saw a small but statistically significant increase in *dihydrotestosterone* (DHT) after supplementing with creatine for 21 days. When DHT, a potent metabolite of <u>testosterone</u>, binds to DHT receptors on the hair follicles of the scalp, those follicles may shrink and stop producing hair. [406][407]

To date, this RCT is the only one to have tested creatine's effects on DHT. However, a number of RCTs

have examined creatine's effects on testosterone. Out of 12 additional RCTs, two saw a significant increase in testosterone, [408][409] but 10 saw no effect. [405][410][411][412][413][414][415][416][417][418] Of those 12 RCTs, five also tested creatine's effects on <u>free testosterone</u>, the form that gets converted into DHT, and all saw no significant increases. [410][411][413][415][417]

#### A proposed mechanism behind creatine's effect on testosterone



Creatine *could* nonsignificantly increase free testosterone yet significantly increase DHT (i.e., a small increase in free testosterone, which can convert into DHT, could lead to a much greater increase in total DHT). So while it's *technically* possible that creatine might have some effect on hair loss, current evidence and mechanistic data indicate it's quite unlikely.

#### A summary of creatine-testosterone studies

BETWEEN- GROUP EFFECT	STUDY	SAMPLE SIZE	POPULATION	AVG AGE	DURATION	DOSE	EFFECT ON TESTOSTERONE
Significant	<u>Arazi 2015</u>	20	Active males	20	1 week	20 g/day	<b>↑</b>
	Vatani 2011	20	Trained males	20	6 days	20 g/day	<b>↑</b>
Mixed Results	van der Merwe 2009	20	Male rugby players	18	3 weeks	25 g/day loading 5 g/day maintenance	↑ DHT
No effect	Cook 2011		Male rugby players	20	10 weeks	4.5 g and 9 g	<b>*</b>
	Cooke 2014	20	Active males	61	12 weeks	20 g/day loading  Then 0.1 g/kg 3x/week (avg. 8.8 g/day)	•
	<u>Crowe 2003</u>	28	Male rugby players	25	6 weeks	3 g/day HMB* + 3 g/day creatine	<b>↔</b>
	Eijnde 2001	11	untrained males	20	8 days	20 g/day	<b>*</b>
	Faraji 2010	20	Male Sprinters	21	1 week	20 g/day	<b>*</b>
	Hoffman 2006	33	Male football players	College	10 weeks	10.5 g/day	<b>+</b>
	Rhimi 2010	27	Trained males	21	1 week	20 g/day	<b>↔</b>

BETWEEN- GROUP EFFECT	STUDY	SAMPLE SIZE	POPULATION	AVG AGE	DURATION	DOSE	EFFECT ON TESTOSTERONE
	<u>Tyka</u> 2015**	19	Male runners	19– 30***	6 weeks	0.07 g/kg of lean body mass	<b>*</b>
	<u>Volek 1997</u>	13	Active males	23	1 week	25 g/day	<b></b>
	Volek 2004	17	Trained males	21	6 weeks	20 g/day loading 4 g/day maintenance	•

<sup>\*</sup> While there was no creatine-only group, studies have not shown HMB to independently affect testosterone. [419][420][421][422]

<sup>\*\*</sup> This study used creatine malate instead of creatine monohydrate.

<sup>\*\*\*</sup> This study reported an age range but not an average age.

### References

- 1. Ruta Ganceviciene, Aikaterini I Liakou, Athanasios Theodoridis, Evgenia Makrantonaki, Christos C Zouboulis Skin anti-aging strategies. Dermatoendocrinol. (2012 Jul 1)
- 2. J L Contet-Audonneau, C Jeanmaire, G Pauly A histological study of human wrinkle structures: comparison between sunexposed areas of the face, with or without wrinkles, and sun-protected areas. *Br J Dermatol.* (1999 Jun)
- 3. Shoubing Zhang, Enkui Duan Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transplant. (2018 May)
- 4. Jean Krutmann, Anne Bouloc, Gabrielle Sore, Bruno A Bernard, Thierry Passeron <u>The Skin Aging Exposome</u>. *J Dermatol Sci.* (2017 Mar)
- 5. Drakaki E et al. Air pollution and the skin. Front. Environ. Sci.. (2014 May)
- 6. Pooja Mally, Craig N Czyz, Allan E Wulc The Role of Gravity in Periorbital and Midfacial Aging. Aesthet Surg J. (2014 Aug)
- 7. John Hatzis The wrinkle and its measurement -- a skin surface Profilometric method. Micron. (2004)
- 8. M Akdeniz, S Gabriel, A Lichterfeld-Kottner, U Blume-Peytavi, J Kottner <u>Transepidermal water loss in healthy adults: a systematic review and meta-analysis update</u>. *Br J Dermatol.* (2018 Nov)
- 9. Esko Alanen, Jouni Nuutinen, Kirsi Nicklén, Tapani Lahtinen, Jukka Mönkkönen Measurement of hydration in the stratum corneum with the MoistureMeter and comparison with the Corneometer. Skin Res Technol. (2004 Feb)
- Fluhr JW et al Comparative study of five instruments measuring stratum corneum hydration (Corneometer CM 820 and CM 825, Skicon 200, Nova DPM 9003, DermaLab). Part II. In vivo. Skin Research & Technology. (1999-08)
- 11. Tamara Agnew, Gareth Furber, Matthew Leach, Leonie Segal A Comprehensive Critique and Review of Published Measures of Acne Severity. J Clin Aesthet Dermatol. (2016 Jul)
- 12. Sophie Nutten Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. (2015)
- 13. Stephan Weidinger, Natalija Novak Atopic dermatitis. Lancet. (2016 Mar 12)
- 14. S R Feldman, G G Krueger Psoriasis assessment tools in clinical trials. Ann Rheum Dis. (2005 Mar)
- 15. J Tan, L M C Almeida, A Bewley, B Cribier, N C Dlova, R Gallo, G Kautz, M Mannis, H H Oon, M Rajagopalan, M Steinhoff, D Thiboutot, P Troielli, G Webster, Y Wu, E J van Zuuren, M Schaller <u>Updating the diagnosis</u>, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. *Br J Dermatol.* (2017 Feb)
- 16. Arnold P Oranje <u>Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score</u>. *Curr Probl Dermatol.* (2011)
- 17. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis.

  \*Dermatology.\*\* (1993)
- 18. J M Hanifin, M Thurston, M Omoto, R Cherill, S J Tofte, M Graeber <u>The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol.</u> (2001 Feb)
- 19. Sarvajnamurthy Aradhya Sacchidanand, Koushik Lahiri, Kiran Godse, Narendra Gajanan Patwardhan, Anil Ganjoo, Rajendra Kharkar, Varsha Narayanan, Dhammraj Borade, Lyndon D'souza <u>Synchronizing Pharmacotherapy in Acne with Review of Clinical Care</u>. *Indian J Dermatol*. (Jul-Aug 2017)
- 20. Stanisław Jarmuda, Niamh O'Reilly, Ryszard Żaba, Oliwia Jakubowicz, Andrzej Szkaradkiewicz, Kevin Kavanagh Potential role of Demodex mites and bacteria in the induction of rosacea. *J Med Microbiol.* (2012 Nov)
- 21. Mark Boguniewicz, Donald Y M Leung Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. *Immunol Rev.* (2011 Jul)
- 22. Francesca Lolli, Francesco Pallotti, Alfredo Rossi, Maria C Fortuna, Gemma Caro, Andrea Lenzi, Andrea Sansone, Francesco Lombardo <u>Androgenetic alopecia: a review</u>. *Endocrine*. (2017 Jul)
- 23. Hind M Almohanna, Azhar A Ahmed, John P Tsatalis, Antonella Tosti <u>The Role of Vitamins and Minerals in Hair Loss: A Review.</u>

  Dermatol Ther (Heidelb). (2019 Mar)
- 24. Cristina Fortes, S Mastroeni, T Mannooranparampil, D Abeni, A Panebianco Mediterranean diet: fresh herbs and fresh vegetables decrease the risk of Androgenetic Alopecia in males. *Arch Dermatol Res.* (2018 Jan)
- 25. C Herbert Pratt, Lloyd E King Jr, Andrew G Messenger, Angela M Christiano, John P Sundberg <u>Alopecia areata</u>. *Nat Rev Dis Primers*. (2017 Mar 16)
- 26. Josef Symon Salgado Concha, Victoria P Werth Alopecias in lupus erythematosus. Lupus Sci Med. (2018 Oct 25)
- F D'Agostini, R Balansky, C Pesce, P Fiallo, R A Lubet, G J Kelloff, S De Flora <u>Induction of alopecia in mice exposed to cigarette smoke</u>. Toxicol Lett. (2000 Apr 3)
- 28. Valentin Galitovskiy, Alexander I Chernyavsky, Robert A Edwards, Sergei A Grando Muscle sarcomas and alopecia in A/J mice chronically treated with nicotine. *Life Sci.* (2012 Nov 27)
- 29. Serge Ahouansou, Philippe Le Toumelin, Béatrice Crickx, Vincent Descamps <u>Association of androgenetic alopecia and hypertension</u>. *Eur J Dermatol.* (May-Jun 2007)

- 30. Aman Samrao, Jennifer M Fu, Steven T Harris, Vera H Price <u>Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids</u>. *J Drugs Dermatol.* (2013 Feb)
- 31. James Gatherwright, Mengyuan T Liu, Bardia Amirlak, Christy Gliniak, Ali Totonchi, Bahman Guyuron <u>The contribution of endogenous and exogenous factors to male alopecia: a study of identical twins. Plast Reconstr Surg.</u> (2013 May)
- 32. I K Yeo, W S Jang, P K Min, H R Cho, S W Cho, N S Hong, J S Kang, D H Ki, H J Kim, Y C Kim, Y S Kim, I J Lee, S W Lee, E S Lim, D C Moon, K H Nam, C K Oho, S W Park, K S Shin, H C Yoo, C K Hong <u>An epidemiological study of androgenic alopecia in 3114 Korean patients</u>. *Clin Exp Dermatol.* (2014 Jan)
- 33. Sanjeev Gupta, Ishan Goyal, Aneet Mahendra Quality of Life Assessment in Patients with Androgenetic Alopecia. Int J Trichology. (Jul-Aug 2019)
- 34. Ralph M Trüeb <u>Association between smoking and hair loss: another opportunity for health education against smoking?</u>. *Dermatology.* (2003)
- 35. Lin-Hui Su, Tony Hsiu-Hsi Chen <u>Association of androgenetic alopecia with smoking and its prevalence among Asian men: a community-based survey. *Arch Dermatol.* (2007 Nov)</u>
- 36. Chao-Chun Yang, Fu-Nien Hsieh, Li-Yu Lin, Chao-Kai Hsu, Hamm-Ming Sheu, WenChieh Chen <u>Higher body mass index is associated with greater severity of alopecia in men with male-pattern androgenetic alopecia in Taiwan: a cross-sectional study.</u> *J Am Acad Dermatol.* (2014 Feb)
- 37. Rita V Vora, Rahul Krishna Suresh Kumar Kota, Rochit R Singhal, Gopikrishnan Anjaneyan <u>Clinical Profile of Androgenic Alopecia</u> and Its Association with <u>Cardiovascular Risk Factors</u>. *Indian J Dermatol.* (Jan-Feb 2019)
- 38. Kamal Sharma, Dhammdeep Humane, Komal Shah, Sachin Patil, Riyaz Charaniya, Jayesh Meniya Androgenic alopecia, premature graying, and hair thinning as independent predictors of coronary artery disease in young Asian males. *Cardiovasc Endocrinol.* (2017 Nov 15)
- 39. Cristina Fortes, Simona Mastroeni, Thomas J Mannooranparampil, Marcella Ribuffo <u>The combination of overweight and smoking increases the severity of androgenetic alopecia</u>. *Int J Dermatol.* (2017 Aug)
- 40. Sang-Yeon Park, Sung Soo Oh, Won-Soo Lee Relationship between androgenetic alopecia and cardiovascular risk factors according to BASP classification in Koreans. *J Dermatol.* (2016 Nov)
- 41. Hima Gopinath, Gatha M Upadya <u>Metabolic syndrome in androgenic alopecia</u>. *Indian J Dermatol Venereol Leprol.* (Jul-Aug 2016)
- 42. Emine Colgecen, Huseyin Ede, Mustafa Fatih Erkoc, Yurdanur Akyuz, Ali Riza Erbay <u>The Relation of Androgenetic Alopecia Severity with Epicardial Fat Thickness</u>. *Ann Dermatol.* (2016 Apr)
- 43. S Chakrabarty, R Hariharan, Dg Gowda, Hemalini Suresh <u>Association of premature androgenetic alopecia and metabolic syndrome in a young Indian population</u>. *Int J Trichology*. (2014 Apr)
- 44. Ola Ahmed Bakry, Mohamed Abdel Moneim Shoeib, Maather Kamel El Shafiee, Ahmed Hassan Androgenetic alopecia, metabolic syndrome, and insulin resistance: Is there any association? A case-control study. Indian Dermatol Online J. (2014 Jul)
- 45. Lin-Hui Su, Hsiu-Hsi Chen Androgenetic alopecia in policemen: higher prevalence and different risk factors relative to the general population (KCIS no. 23). Arch Dermatol Res. (2011 Dec)
- 46. Päivi Hirsso, Ulla Rajala, Liisa Hiltunen, Jari Jokelainen, Sirkka Keinänen-Kiukaanniemi, Simo Näyhä Obesity and low-grade inflammation among young Finnish men with early-onset alopecia. *Dermatology*. (2007)
- 47. Veikko Matilainen, Mauri Laakso, Päivi Hirsso, Pentti Koskela, Ulla Rajala, Sirkka Keinänen-Kiukaanniemi <u>Hair loss, insulin resistance, and heredity in middle-aged women. A population-based study</u>. *J Cardiovasc Risk*. (2003 Jun)
- 48. D J Piacquadio, F S Rad, M C Spellman, K A Hollenbach Obesity and female androgenic alopecia: a cause and an effect?. J Am Acad Dermatol. (1994 Jun)
- 49. Kubra Esen Salman, Ilknur Kivanc Altunay, Nihal Asli Kucukunal, Asli Aksu Cerman Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital-based cross-sectional study in Turkey. *An Bras Dermatol.* (Jan-Feb 2017)
- 50. Seyran Ozbas Gok, Asli Akin Belli, Emine Dervis <u>Is There Really Relationship between Androgenetic Alopecia and Metabolic Syndrome?</u>. *Dermatol Res Pract.* (2015)
- 51. Ceyda Mumcuoglu, Tugba Rezan Ekmekci, Sema Ucak <u>The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia</u>. *Eur J Dermatol.* (Jan-Feb 2011)
- 52. José Gerardo González-González, Leonardo G Mancillas-Adame, Mercedes Fernández-Reyes, Minerva Gómez-Flores, Fernando Javier Lavalle-González, Jorge Ocampo-Candiani, Jesús Zacarías Villarreal-Pérez <u>Androgenetic alopecia and insulin resistance in young men. Clin Endocrinol (Oxf).</u> (2009 Oct)
- 53. G Severi, R Sinclair, J L Hopper, D R English, M R E McCredie, P Boyle, G G Giles <u>Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors.</u> *Br J Dermatol.* (2003 Dec)
- 54. Zhang B et al Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. Nature. (2020-01-22)
- 55. Sérgio Schalka, Denise Steiner, Flávia Naranjo Ravelli, Tatiana Steiner, Aripuanã Cobério Terena, Carolina Reato Marçon, Eloisa Leis Ayres, Flávia Alvim Sant'anna Addor, Helio Amante Miot, Humberto Ponzio, Ida Duarte, Jane Neffá, José Antônio Jabur da Cunha, Juliana Catucci Boza, Luciana de Paula Samorano, Marcelo de Paula Corrêa, Marcus Maia, Nilton Nasser, Olga Maria Rodrigues Ribeiro Leite, Otávio Sergio Lopes, Pedro Dantas Oliveira, Renata Leal Bregunci Meyer, Tânia Cestari, Vitor Manoel

- Silva dos Reis, Vitória Regina Pedreira de Almeida Rego, Brazilian Society of Dermatology <u>Brazilian Consensus on Photoprotection</u>. *An Bras Dermatol*. (Nov-Dec 2014)
- 56. Uraiwan Panich, Gunya Sittithumcharee, Natwarath Rathviboon, Siwanon Jirawatnotai <u>Ultraviolet Radiation-Induced Skin Aging: The Role of DNA Damage and Oxidative Stress in Epidermal Stem Cell Damage Mediated Skin Aging. Stem Cells Int.</u> (2016)
- 57. Barbara A Gilchrest Photoaging. J Invest Dermatol. (2013 Jul 1)
- 58. D S Rigel, E G Rigel, A C Rigel Effects of altitude and latitude on ambient UVB radiation. J Am Acad Dermatol. (1999 Jan)
- 59. Nawaf Labban, Hanan Al-Otaibi, Abdulaziz Alayed, Khaled Alshankiti, Mohammad A Al-Enizy Assessment of the influence of gender and skin color on the preference of tooth shade in Saudi population. Saudi Dent J. (2017 Jul)
- 60. Steven Eilers, Daniel Q Bach, Rikki Gaber, Hanz Blatt, Yanina Guevara, Katie Nitsche, Roopal V Kundu, June K Robinson Accuracy of self-report in assessing Fitzpatrick skin phototypes I through VI. JAMA Dermatol. (2013 Nov)
- 61. John D'Orazio, Stuart Jarrett, Alexandra Amaro-Ortiz, Timothy Scott UV radiation and the skin. Int J Mol Sci. (2013 Jun 7)
- 62. Carolyn J Heckman, Rachel Chandler, Jacqueline D Kloss, Amy Benson, Deborah Rooney, Teja Munshi, Susan D Darlow, Clifford Perlis, Sharon L Manne, David W Oslin Minimal Erythema Dose (MED) testing. J Vis Exp. (2013 May 28)
- 63. P J Matts, P J Dykes, R Marks The distribution of melanin in skin determined in vivo. Br J Dermatol. (2007 Apr)
- 64. Susanne Astner, R Rox Anderson Skin phototypes 2003. J Invest Dermatol. (2004 Feb)
- 65. T B Fitzpatrick The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. (1988 Jun)
- 66. FDA CFR Code of Federal Regulations Title 21 (21CFR201.327).
- 67. U Osterwalder, B Herzog Sun protection factors: world wide confusion. Br J Dermatol. (2009 Nov)
- 68. Sergio Schalka, Vitor Manoel Silva Dos Reis <u>Sun protection factor: meaning and controversies</u>. *An Bras Dermatol.* (May-Jun 2011)
- 69. Bibi Petersen, Hans Christian Wulf <u>Application of sunscreen--theory and reality</u>. *Photodermatol Photoimmunol Photomed*. (Apr-Jun 2014)
- 70. Ashley R Heurung, Srihari I Raju, Erin M Warshaw <u>Adverse reactions to sunscreen agents: epidemiology, responsible irritants and allergens, clinical characteristics, and management</u>. *Dermatitis*. (Nov-Dec 2014)
- 71. Ashley R Heurung, Srihari I Raju, Erin M Warshaw Benzophenones. Dermatitis. (Jan-Feb 2014)
- 72. C T Jansén, G Wennersten, I Rystedt, P Thune, H Brodthagen <u>The Scandinavian standard photopatch test procedure</u>. *Contact Dermatitis*. (1982 May)
- 73. P Thune, C Jansén, G Wennersten, I Rystedt, H Brodthagen, N McFadden <u>The Scandinavian multicenter photopatch study</u> 1980-1985: final report. *Photodermatol.* (1988 Dec)
- 74. Melanie D Palm, Marianne N O'Donoghue <u>Update on photoprotection</u>. *Dermatol Ther.* (Sep-Oct 2007)
- 75. Melody J Eide, Martin A Weinstock <u>Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol. (2005 Apr)</u>
- 76. NIH SEER Program SEER Incidence and US Death Rates: Melanoma of the Skin, Both Sexes.
- 77. Alpana K Gupta, Mausumi Bharadwaj, Ravi Mehrotra <u>Skin Cancer Concerns in People of Color: Risk Factors and Prevention</u>. *Asian Pac J Cancer Prev*. (2016 Dec 1)
- 78. Hao Ou-Yang, Joseph Stanfield, Curtis Cole, Yohini Appa, Darrell Rigel <u>High-SPF sunscreens (SPF ≥ 70) may provide ultraviolet protection above minimal recommended levels by adequately compensating for lower sunscreen user application amounts.</u> *J Am Acad Dermatol.* (2012 Dec)
- 79. P Autier, M Boniol, G Severi, J F Doré, European Organizatin for Research and Treatment of Cancer Melanoma Co-operative Group Quantity of sunscreen used by European students. *Br J Dermatol.* (2001 Feb)
- 80. Rachel Neale, Gail Williams, Adèle Green Application patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol. (2002 Oct)
- 81. Grosick T et al Efficacy as used, not as tested, is true measure of sunscreen performance. JAAD. (2004 Mar)
- 82. Calbó J et al Empirical studies of cloud effects on UV radiation: A review. Rev. Geophys.. (2005 Jun)
- 83. Ann R Webb, Andreas Kazantzidis, Richard C Kift, Mark D Farrar, Jack Wilkinson, Lesley E Rhodes <u>Colour Counts: Sunlight and Skin Type as Drivers of Vitamin D Deficiency at UK Latitudes</u>. *Nutrients*. (2018 Apr 7)
- 84. Ann R Webb, Andreas Kazantzidis, Richard C Kift, Mark D Farrar, Jack Wilkinson, Lesley E Rhodes Meeting Vitamin D Requirements in White Caucasians at UK Latitudes: Providing a Choice. Nutrients. (2018 Apr 17)
- 85. Joshua D Williams, Prithwiraj Maitra, Evren Atillasoy, Mei-Miau Wu, Aaron S Farberg, Darrell S Rigel SPF 100+ sunscreen is more protective against sunburn than SPF 50+ in actual use: Results of a randomized, double-blind, split-face, natural sunlight exposure clinical trial. J Am Acad Dermatol. (2018 May)
- 86. Julie E Russak, Theresa Chen, Yohini Appa, Darrell S Rigel <u>A comparison of sunburn protection of high-sun protection factor</u> (SPF) sunscreens: SPF 85 sunscreen is significantly more protective than SPF 50. *J Am Acad Dermatol.* (2010 Feb)

- 87. Mantas Grigalavicius, Vladimir Iani, Asta Juzeniene <u>Layer Thickness of SPF 30 Sunscreen and Formation of Pre-vitamin D.</u> *Anticancer Res.* (2016 Mar)
- 88. Stephan Lautenschlager, Hans Christian Wulf, Mark R Pittelkow Photoprotection. Lancet. (2007 Aug 11)
- 89. R Stokes, B Diffey How well are sunscreen users protected?. Photodermatol Photoimmunol Photomed. (Oct-Dec 1997)
- 90. Sang Min Kim, Byung Ho Oh, Yang Won Lee, Yong Beom Choe, Kyu Joong Ahn <u>The relation between the amount of sunscreen applied and the sun protection factor in Asian skin</u>. *J Am Acad Dermatol*. (2010 Feb)
- 91. Makoto Mizuno, Kayo Kunimoto, Eiji Naru, Koichi Kameyama, Fukumi Furukawa, Yuki Yamamoto <u>The effects of continuous application of sunscreen on photoaged skin in Japanese elderly people the relationship with the usage</u>. *Clin Cosmet Investig Dermatol.* (2016 Apr 26)
- 92. Kasey L Morris, Frank M Perna <u>Decision Tree Model vs Traditional Measures to Identify Patterns of Sun-Protective Behaviors and Sun Sensitivity Associated With Sunburn</u>. *JAMA Dermatol.* (2018 Aug 1)
- 93. Maria Yusuf Dhariwala, Padmini Ravikumar <u>An overview of herbal alternatives in androgenetic alopecia</u>. *J Cosmet Dermatol.* (2019 Aug)
- 94. Ds Krupa Shankar, M Chakravarthi, Rachana Shilpakar Male androgenetic alopecia: population-based study in 1,005 subjects. Int J Trichology. (2009 Jul)
- 95. G R Zins The history of the development of minoxidil. Clin Dermatol. (Oct-Dec 1988)
- 96. Adil A, Godwin M The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. (2017 Jul)
- 97. Esther J van Zuuren, Zbys Fedorowicz, Jan Schoones <u>Interventions for female pattern hair loss</u>. *Cochrane Database Syst Rev.* (2016 May 26)
- 98. Aditya K Gupta, Andrew Charrette <u>Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia</u>. *Skinmed*. (May-Jun 2015)
- 99. V Kanti, A Messenger, G Dobos, P Reygagne, A Finner, A Blumeyer, M Trakatelli, A Tosti, V Del Marmol, B M Piraccini, A Nast, U Blume-Peytavi Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men short version.

  J Eur Acad Dermatol Venereol. (2018 Jan)
- 100. R L De Villez Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol. (1985 Feb)
- 101. G S Bazzano, N Terezakis, W Galen Topical tretinoin for hair growth promotion. J Am Acad Dermatol. (1986 Oct)
- 102. Hyo Seung Shin, Chong Hyun Won, Seung Ho Lee, Oh Sang Kwon, Kyu Han Kim, Hee Chul Eun Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol. (2007)
- 103. Ganniga Pumthong, Pravit Asawanonda, Supenya Varothai, Vorapicha Jariyasethavong, Daranporn Triwongwaranat, Puan Suthipinittharm, Kornkanok Ingkaninan, Pimporn Leelapornpisit, Neti Waranuch <u>Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebocontrolled study.</u> J Dermatolog Treat. (2012 Oct)
- 104. Berger RS, Fu JL, Smiles KA, Turner CB, Schnell BM, Werchowski KM, Lammers KM The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. *Br J Dermatol.* (2003 Aug)
- 105. Hwa Jung Ryu, Min Gun Yoo, Sang Wook Son <u>The efficacy of 3% minoxidil vs. combined 3% minoxidil and Korean red ginseng in treating female pattern alopecia</u>. *Int J Dermatol.* (2014 Jun)
- 106. Hamidreza Pazoki-Toroudi, Shahab Babakoohi, Mohammad Ali Nilforoushzadeh, Mansour Nassiri-Kashani, Mohammad Shizarpour, Marjan Ajami, Rouhollah Habibey, Bardia Sadr, Mehdi Rashighi-Firoozabadi, Alireza Firooz Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. *Skinmed*. (Sep-Oct 2012)
- 107. Poonkiat Suchonwanit, Wimolsiri lamsumang, Salinee Rojhirunsakool Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. Am J Clin Dermatol. (2019 Feb)
- 108. Farouk M Sakr, Ali Mi Gado, Haseebur R Mohammed, Abdel Nasser Ismail Adam Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. Drug Des Devel Ther. (2013 May 30)
- 109. Sujay Khandpur, Mansi Suman, Belum Sivanagi Reddy <u>Comparative efficacy of various treatment regimens for androgenetic alopecia in men</u>. *J Dermatol.* (2002 Aug)
- 110. Rachita Dhurat, Ms Sukesh, Ganesh Avhad, Ameet Dandale, Anjali Pal, Poonam Pund <u>A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study</u>. *Int J Trichology*. (2013 Jan)
- 111. Kaksha B Shah, Aarti N Shah, Rekha B Solanki, Ranjan C Raval A Comparative Study of Microneedling with Platelet-rich Plasma Plus Topical Minoxidil (5%) and Topical Minoxidil (5%) Alone in Androgenetic Alopecia. *Int J Trichology*. (Jan-Mar 2017)
- 112. Edward S Friedman, Paul M Friedman, David E Cohen, Ken Washenik <u>Allergic contact dermatitis to topical minoxidil solution:</u> etiology and treatment. *J Am Acad Dermatol.* (2002 Feb)
- 113. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ <u>A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.</u> *J Am Acad Dermatol.* (2002 Sep)

- 114. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B <u>A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. (2007 Nov)</u>
- 115. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD <u>A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.</u> *J Am Acad Dermatol.* (2004 Apr)
- 116. Andy Goren, Ty Naccarato Minoxidil in the treatment of androgenetic alopecia. Dermatol Ther. (2018 Sep)
- 117. Vogt A et al. Biology of the Hair Follicle. Hair Growth and Disorders. (2006)
- 118. Schreiber R, Taschler U, Preiss-Landl K, Wongsiriroj N, Zimmermann R, Lass A Retinyl ester hydrolases and their roles in vitamin A homeostasis. Biochim Biophys Acta. (2012 Jan)
- 119. O'Byrne SM, Blaner WS Retinol and retinyl esters: biochemistry and physiology. J Lipid Res. (2013 Jul)
- 120. J L López-Estebaranz, P Herranz-Pinto, B Dréno, el grupo de dermatólogos expertos en acné <u>Consensus-Based Acne</u> <u>Classification System and Treatment Algorithm for Spain</u>. *Actas Dermosifiliogr*. (2017 Mar)
- 121. Diane Thiboutot, Harald Gollnick, Vincenzo Bettoli, Brigitte Dréno, Sewon Kang, James J Leyden, Alan R Shalita, Vicente Torres Lozada, Diane Berson, Andrew Finlay, Chee Leok Goh, María Isabel Herane, Ana Kaminsky, Raj Kubba, Alison Layton, Yoshiki Miyachi, Montserrat Perez, Jaime Piquero Martin, Marcia Ramos-E-Silva, Jo Ann See, Neil Shear, John Wolf Jr, Global Alliance to Improve Outcomes in Acne New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. (2009 May)
- 122. Lawrence F Eichenfield, Andrew C Krakowski, Caroline Piggott, James Del Rosso, Hilary Baldwin, Sheila Fallon Friedlander, Moise Levy, Anne Lucky, Anthony J Mancini, Seth J Orlow, Albert C Yan, Keith K Vaux, Guy Webster, Andrea L Zaenglein, Diane M Thiboutot, American Acne and Rosacea Society Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. (2013 May)
- 123. A Nast, B Dréno, V Bettoli, Z Bukvic Mokos, K Degitz, C Dressler, A Y Finlay, M Haedersdal, J Lambert, A Layton, H B Lomholt, J L López-Estebaranz, F Ochsendorf, C Oprica, S Rosumeck, T Simonart, R N Werner, H Gollnick <u>European evidence-based (S3) guideline for the treatment of acne update 2016 short version</u>. *J Eur Acad Dermatol Venereol*. (2016 Aug)
- 124. James Leyden, Linda Stein-Gold, Jonathan Weiss Why Topical Retinoids Are Mainstay of Therapy for Acne. Dermatol Ther (Heidelb). (2017 Sep)
- 125. Marge Nighland, Rachel Grossman <u>Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis</u>. *J Drugs Dermatol.* (2008 Aug)
- 126. James J Leyden Meta-analysis of topical tazarotene in the treatment of mild to moderate acne. Cutis. (2004 Oct)
- 127. Leonora Culp, Sara Moradi Tuchayi, Hossein Alinia, Steven R Feldman <u>Tolerability of Topical Retinoids: Are There Clinically Meaningful Differences Among Topical Retinoids?</u>. *J Cutan Med Surg.* (Nov-Dec 2015)
- 128. W J Cunliffe, M Poncet, C Loesche, M Verschoore <u>A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. *Br J Dermatol.* (1998 Oct)</u>
- 129. Bradley A Hubbard, Jacob G Unger, Rod J Rohrich Reversal of skin aging with topical retinoids. Plast Reconstr Surg. (2014 Apr)
- 130. A Chiu, A B Kimball <u>Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage</u>. *Br J Dermatol.* (2003 Oct)
- 131. Ryan R Riahi, Amelia E Bush, Philip R Cohen <u>Topical Retinoids: Therapeutic Mechanisms in the Treatment of Photodamaged Skin. Am J Clin Dermatol.</u> (2016 Jun)
- 132. A C Green, M C B Hughes, P McBride, A Fourtanier <u>Factors associated with premature skin aging (photoaging) before the age of 55: a population-based study</u>. *Dermatology*. (2011 Feb)
- 133. Erica C Davis, Valerie D Callender Aesthetic dermatology for aging ethnic skin. Dermatol Surg. (2011 Jul)
- 134. M Samuel, R C C Brooke, S Hollis, C E M Griffiths <u>Interventions for photodamaged skin</u>. *Cochrane Database Syst Rev.* (2005 Jan 25)
- 135. Sewon Kang, Michael T Goldfarb, Jonathan S Weiss, Russell D Metz, Ted A Hamilton, John J Voorhees, Christopher E M Griffiths Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. *J Am Acad Dermatol.* (2003 Jul)
- 136. María Isabel Herane, Cecilia Orlandi, Emilia Zegpi, Pilar Valdés, Ximena Ancić Clinical efficacy of adapalene (differin(®)) 0.3% gel in Chilean women with cutaneous photoaging. *J Dermatolog Treat*. (2012 Feb)
- 137. C Green, G Orchard, R Cerio, J L Hawk <u>A clinicopathological study of the effects of topical retinyl propionate cream in skin photoageing</u>. *Clin Exp Dermatol*. (1998 Jul)
- 138. Michael Babcock, Rahul C Mehta, Elizabeth T Makino <u>A randomized, double-blind, split-face study comparing the efficacy and tolerability of three retinol-based products vs. three tretinoin-based products in subjects with moderate to severe facial photodamage. *J Drugs Dermatol.* (2015 Jan)</u>
- 139. Manpreeet Randhawa, Dianne Rossetti, James J Leyden, Jared Fantasia, Joshua Zeichner, Gabriela Oana Cula, Michael Southall, Samantha Tucker-Samaras <u>One-year topical stabilized retinol treatment improves photodamaged skin in a double-blind, vehicle-controlled trial</u>. *J Drugs Dermatol*. (2015 Mar)
- 140. Elizabeth T Ho, Nathan S Trookman, Brian R Sperber, Ronald L Rizer, Ralph Spindler, Sujatha Sonti, Vincent Gotz, Rahul Mehta

- A randomized, double-blind, controlled comparative trial of the anti-aging properties of non-prescription tri-retinol 1.1% vs. prescription tretinoin 0.025%. *J Drugs Dermatol.* (2012 Jan)
- 141. P Creidi, M P Vienne, S Ochonisky, C Lauze, V Turlier, J M Lagarde, P Dupuy <u>Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment</u>. *J Am Acad Dermatol*. (1998 Dec)
- 142. Y C Kaplan, J Ozsarfati, F Etwel, C Nickel, I Nulman, G Koren <u>Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis</u>. *Br J Dermatol.* (2015 Nov)
- 143. Anna L Chien, Ji Qi, Barbara Rainer, Dana L Sachs, Yolanda R Helfrich <u>Treatment of Acne in Pregnancy</u>. *J Am Board Fam Med*. (Mar-Apr 2016)
- 144. Sree S Kolli, Danielle Pecone, Adrian Pona, Abigail Cline, Steven R Feldman <u>Topical Retinoids in Acne Vulgaris: A Systematic Review.</u> *Am J Clin Dermatol.* (2019 Jun)
- 145. D Thiboutot, M H Gold, M T Jarratt, S Kang, D L Kaplan, L Millikan, J Wolfe, C Loesche, M Baker <u>Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris.</u> Cutis. (2001 Oct)
- 146. William J Cunliffe, F William Danby, Frank Dunlap, Michael H Gold, David Gratton, Alan Greenspan Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol. (Jul-Aug 2002)
- 147. G F Webster, D Berson, L F Stein, D P Fivenson, E A Tanghetti, M Ling Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. *Cutis.* (2001 Jun)
- 148. A Shalita, B Miller, A Menter, W Abramovits, K Loven, L Kakita <u>Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study</u>. *J Drugs Dermatol.* (Mar-Apr 2005)
- 149. Guy F Webster, Lyn Guenther, Yves P Poulin, Barry A Solomon, Keith Loven, Jeff Lee A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adaptalene 0.1% gel for the treatment of facial acne vulgaris. *Cutis.* (2002 Feb)
- 150. Diane Thiboutot, Stephanie Arsonnaud, Pascale Soto Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. *J Drugs Dermatol.* (2008 Jun)
- 151. S A Galvin, R Gilbert, M Baker, F Guibal, M R Tuley <u>Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations</u>. *Br J Dermatol.* (1998 Oct)
- 152. James Del Rosso, Julie Harper, Radhakrishnan Pillai, Robert Moore <u>Tretinoin photostability: comparison of micronized tretinoin gel 0.05% and tretinoin gel 0.025% following exposure to fluorescent and solar light. J Clin Aesthet Dermatol. (2013 Feb)</u>
- 153. Marge Nighland, Mohammed Yusuf, Stephen Wisniewski, Kate Huddleston, Judit Nyirady <u>The effect of simulated solar UV irradiation on tretinoin gel microsphere 0.1% and tretinoin gel 0.025%</u>. *Cutis.* (2006 May)
- 154. James Q Del Rosso, Julie Harper, Radhakrishnan Pillai, Robert Moore <u>Tretinoin photostability: comparison of micronized tretinoin (0.05%) gel and tretinoin (0.025%) gel following exposure to ultraviolet a light. *J Clin Aesthet Dermatol.* (2012 Jan)</u>
- 155. Helen M Torok, Radhakrishan Pillai <u>Safety and efficacy of micronized tretinoin gel (0.05%) in treating adolescent acne.</u> *J Drugs Dermatol.* (2011 Jun)
- 156. Anne W Lucky, Jeffrey Sugarman Comparison of micronized tretinoin gel 0.05% and tretinoin gel microsphere 0.1% in young adolescents with acne: a post hoc analysis of efficacy and tolerability data. Cutis. (2011 Jun)
- 157. A W Lucky, S I Cullen, M T Jarratt, J W Quigley Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol. (1998 Apr)
- 158. Yoon HS, Kim JR, Park GY, Kim JE, Lee DH, Lee KW, Chung JH Cocoa Flavanol Supplementation Influences Skin Conditions of Photo-Aged Women: A 24-Week Double-Blind, Randomized, Controlled Trial. J Nutr. (2016 Jan)
- 159. Heinrich U, Neukam K, Tronnier H, Sies H, Stahl W Long-term ingestion of high flavanol cocoa provides photoprotection against UV-induced erythema and improves skin condition in women. *J Nutr.* (2006 Jun)
- 160. Mogollon JA, Boivin C, Lemieux S, Blanchet C, Claveau J, Dodin S <u>Chocolate flavanols and skin photoprotection: a parallel, double-blind, randomized clinical trial</u>. *Nutr J.* (2014 Jun 27)
- 161. Azila Abdul Karim, Azrina Azlan, Amin Ismail, Puziah Hashim, Siti Salwa Abd Gani, Badrul Hisyam Zainudin, Nur Azilah Abdullah Efficacy of cocoa pod extract as antiwrinkle gel on human skin surface. *J Cosmet Dermatol.* (2016 Sep)
- 162. Williams S, Tamburic S, Lally C <u>Eating chocolate can significantly protect the skin from UV light</u>. *J Cosmet Dermatol.* (2009 Sep.)
- 163. Caperton C, Block S, Viera M, Keri J, Berman B <u>Double-blind</u>, <u>Placebo-controlled Study Assessing the Effect of Chocolate Consumption in Subjects with a History of Acne Vulgaris</u>. *J Clin Aesthet Dermatol*. (2014 May)
- 164. Gregory R Delost, Maria E Delost, Jenifer Lloyd <u>The impact of chocolate consumption on acne vulgaris in college students: A randomized crossover study.</u> J Am Acad Dermatol. (2016 Jul)
- 165. Saivaree Vongraviopap, Pravit Asawanonda <u>Dark chocolate exacerbates acne</u>. Int J Dermatol. (2016 May)
- 166. Samantha G Block, Whitney E Valins, Caroline V Caperton, Martha H Viera, Sadegh Amini, Brian Berman <u>Exacerbation of facial</u> acne vulgaris after consuming pure chocolate. *J Am Acad Dermatol.* (2011 Oct)
- 167. Pearson DA, Paglieroni TG, Rein D, Wun T, Schramm DD, Wang JF, Holt RR, Gosselin R, Schmitz HH, Keen CL The effects of

- flavanol-rich cocoa and aspirin on ex vivo platelet function. Thromb Res. (2002 May 15)
- 168. Muhammad Haseeb Zubair, Muhammad Habib Zubair, Muhammad Naqeeb Zubair, Muhammad Mujeeb Zubair, Tariq Aftab, Farah Asad Augmentation of anti-platelet effects of aspirin. *J Pak Med Assoc.* (2011 Mar)
- 169. Stan Heptinstall, Jane May, Sue Fox, Catherine Kwik-Uribe, Lian Zhao Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J Cardiovasc Pharmacol. (2006)
- 170. Andrew J Innes, Gwen Kennedy, Margaret McLaren, Anne J Bancroft, Jill J F Belch <u>Dark chocolate inhibits platelet aggregation</u> in healthy volunteers. *Platelets.* (2003 Aug)
- 171. EFSA Panel on Dietetic Products Scientific Opinion on the safety of caffeine. JEFSA. (2015 May)
- 172. Planning Committee for a Workshop on Potential Health Hazards Associated with Consumption of Caffeine in Food and Dietary Supplements, Food and Nutrition Board, Board on Health Sciences Policy, Institute of Medicine <a href="Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary">Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary</a>.
- 173. Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M Effects of caffeine on human health. Food Addit Contam. (2003 Jan)
- 174. Louise I Mennen, Ron Walker, Catherine Bennetau-Pelissero, Augustin Scalbert Risks and safety of polyphenol consumption.

  Am J Clin Nutr. (2005 Jan)
- 175. Ma Q, Kim EY, Lindsay EA, Han O Bioactive dietary polyphenols inhibit heme iron absorption in a dose-dependent manner in human intestinal Caco-2 cells. *J Food Sci.* (2011 Jun-Jul)
- 176. R F Hurrell, M Reddy, J D Cook <u>Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages</u>. *Br J Nutr.* (1999 Apr)
- 177. Miller KB, Hurst WJ, Payne MJ, Stuart DA, Apgar J, Sweigart DS, Ou B <u>Impact of alkalization on the antioxidant and flavanol content of commercial cocoa powders</u>. *J Agric Food Chem*. (2008 Sep 24)
- 178. Albertini B, Schoubben A, Guarnaccia D, Pinelli F, Della Vecchia M, Ricci M, Di Renzo GC, Blasi P <u>Effect of fermentation and drying on cocoa polyphenols</u>. *J Agric Food Chem*. (2015 Nov 18)
- 179. Todorovic V, Milenkovic M, Vidovic B, Todorovic Z, Sobajic S <u>Correlation between Antimicrobial, Antioxidant Activity, and Polyphenols of Alkalized (Nonalkalized Cocoa Powders.</u> *J Food Sci.* (2017 Apr)
- 180. Andres-Lacueva C, Monagas M, Khan N, Izquierdo-Pulido M, Urpi-Sarda M, Permanyer J, Lamuela-Raventós RM Flavanol and flavonol contents of cocoa powder products: influence of the manufacturing process. *J Agric Food Chem.* (2008 May 14)
- 181. Faisal Ali, Yazan Ranneh, Amin Ismail, Norhaizan Mohd Esa <u>Identification of phenolic compounds in polyphenols-rich extract of Malaysian cocoa powder using the HPLC-UV-ESI-MS/MS and probing their antioxidant properties</u>. *J Food Sci Technol.* (2015 Apr)
- 182. Francisco A Tomas-Barberan, Elena Cienfuegos-Jovellanos, Alicia Marín, Begoña Muguerza, Angel Gil-Izquierdo, Begoña Cerda, Pilar Zafrilla, Juana Morillas, Juana Mulero, Alvin Ibarra, María A Pasamar, Daniel Ramón, Juan Carlos Espín A new process to develop a cocoa powder with higher flavonoid monomer content and enhanced bioavailability in healthy humans. J Agric Food Chem. (2007 May 16)
- 183. Hollenberg NK, Fisher ND Is it the dark in dark chocolate?. Circulation. (2007 Nov 20)
- 184. Jean-François Bisson, Amine Nejdi, Pascale Rozan, Sophie Hidalgo, Robert Lalonde, Michaël Messaoudi Effects of long-term administration of a cocoa polyphenolic extract (Acticoa powder) on cognitive performances in aged rats. *Br J Nutr.* (2008 Jul)
- 185. Karin Neukam, Wilhelm Stahl, Hagen Tronnier, Helmut Sies, Ulrike Heinrich Consumption of flavanol-rich cocoa acutely increases microcirculation in human skin. Eur J Nutr. (2007 Feb)
- 186. Lamuela-Raventós R et al. Review: Health Effects of Cocoa Flavonoids. Food Sci Technol Int. (2005 Jun)
- 187. Agero AL, Verallo-Rowell VM <u>A randomized double-blind controlled trial comparing extra virgin coconut oil with mineral oil as a moisturizer for mild to moderate xerosis</u>. *Dermatitis*. (2004 Sep)
- 188. de las Alas J et al. Randomized Controlled Trial on the Efficacy and Safety of Virgin Coconut Oil Compared to Mineral Oil in the Treatment of Uremic Xerosis. Acta Med Philipp. (2011)
- 189. Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. (2008 Nov-Dec)
- 190. Mara Therese Padilla Evangelista, Flordeliz Abad-Casintahan, Lillian Lopez-Villafuerte The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind, clinical trial. Int J Dermatol. (2014 Jan)
- 191. Sushma Nangia, Vinod Kumar Paul, Ashok Kumar Deorari, V Sreenivas, Ramesh Agarwal, Deepak Chawla <u>Topical Oil</u>
  <u>Application and Trans-Epidermal Water Loss in Preterm Very Low Birth Weight Infants-A Randomized Trial</u>. *J Trop Pediatr*.
  (2015 Dec)
- 192. Rehana A Salam, Gary L Darmstadt, Zulfiqar A Bhutta Effect of emollient therapy on clinical outcomes in preterm neonates in Pakistan: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. (2015 May)
- 193. Tobias Strunk, Sameer Pupala, Julie Hibbert, Dorota Doherty, Sanjay Patole <u>Topical Coconut Oil in Very Preterm Infants: An Open-Label Randomised Controlled Trial</u>. *Neonatology*. (2018)
- 194. Aguilera-Méndez A et al The Chemistry and Biochemistry of Niacin (B3). B Vitamins and Folate: Chemistry, Analysis, Function

- and Effects. (2013 Oct)
- 195. Zabiolah Shahmoradi, Farib Iraji, Amir Hossein Siadat, Azamosadat Ghorbaini Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. *J Res Med Sci.* (2013 Feb)
- 196. Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ER <u>Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris</u>. *Int J Dermatol.* (2013 Aug)
- 197. Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK <u>Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris</u>. *Int J Dermatol*. (1995 Jun)
- 198. Kaymak Y et al An Investigation of Efficacy of Topical Niacinamide for the Treatment of Mild and Moderate Acne Vulgaris. JTAD. (2008)
- 199. S K Dos, J N Barbhuiya, S Jana, S K Dey Comparative evaluation of clindamycin phosphate 1% and clindamycin phosphate 1% with nicotinamide gel 4% in the treatment of acne vulgaris. *Indian J Dermatol Venereol Leprol.* (Jan-Feb 2003)
- 200. V R Sardesai, V M Kambli Comparison of efficacy of topical clindamycin and nicotinamide combination with plain clindamycin for the treatment of acne vulgaris and acne resistant to topical antibiotics. *Indian J Dermatol Venereol Leprol.* (Mar-Apr 2003)
- 201. P Morganti, E Berardesca, B Guarneri, F Guarneri, G Fabrizi, P Palombo, M Palombo <u>Topical clindamycin 1% vs. linoleic acid-rich phosphatidylcholine and nicotinamide 4% in the treatment of acne: a multicentre-randomized trial. *Int J Cosmet Sci.* (2011 Oct)</u>
- 202. Enzo Emanuele, Marco Bertona, Karmela Altabas, Velimir Altabas, Giuseppe Alessandrini Anti-inflammatory effects of a topical preparation containing nicotinamide, retinol, and 7-dehydrocholesterol in patients with acne: a gene expression study. Clin Cosmet Investig Dermatol. (2012)
- 203. Neil M Niren, Helen M Torok <u>The Nicomide Improvement in Clinical Outcomes Study (NICOS): results of an 8-week trial</u>. *Cutis*. (2006 Jan)
- 204. Alan R Shalita, Ronald Falcon, Alan Olansky, Patricia lannotta, Arash Akhavan, Doris Day, Anthony Janiga, Prashant Singri, John E Kallal Inflammatory acne management with a novel prescription dietary supplement. *J Drugs Dermatol.* (2012 Dec)
- 205. Frances M Walocko, Ariel E Eber, Jonette E Keri, Mana A Al-Harbi, Keyvan Nouri <u>The role of nicotinamide in acne treatment</u>. *Dermatol Ther.* (2017 Sep)
- 206. Andrea L Zaenglein, Arun L Pathy, Bethanee J Schlosser, Ali Alikhan, Hilary E Baldwin, Diane S Berson, Whitney P Bowe, Emmy M Graber, Julie C Harper, Sewon Kang, Jonette E Keri, James J Leyden, Rachel V Reynolds, Nanette B Silverberg, Linda F Stein Gold, Megha M Tollefson, Jonathan S Weiss, Nancy C Dolan, Andrew A Sagan, Mackenzie Stern, Kevin M Boyer, Reva Bhushan Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. (2016 May)
- 207. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE <u>The</u> effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. *Br J Dermatol.* (2002 Jul)
- 208. A B Kimball, J R Kaczvinsky, J Li, L R Robinson, P J Matts, C A Berge, K Miyamoto, D L Bissett Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. Br J Dermatol. (2010 Feb 1)
- 209. Jennifer Schweikart, Jürgen Reimann, Christiane Schön <u>Investigation of niacin on parameters of metabolism in a physiologic dose: randomized, double-blind clinical trial with three different dosages</u>. *Int J Food Sci Nutr.* (2009)
- 210. Clara Minto, Maria Gabriella Vecchio, Manfred Lamprecht, Dario Gregori <u>Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation</u>. *Nutr Rev.* (2017 Jun 1)
- 211. Joel L Cohen Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. (2010 Jun)
- 212. Rashi Minocha, Diona L Damian, Gary M Halliday Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide?. Photodermatol Photoimmunol Photomed. (2018 Jan)
- 213. F J Moloney, H Comber, P O'Lorcain, P O'Kelly, P J Conlon, G M Murphy <u>A population-based study of skin cancer incidence</u> and prevalence in renal transplant recipients. *Br J Dermatol.* (2006 Mar)
- 214. Diona L Damian Nicotinamide for skin cancer chemoprevention. Australas J Dermatol. (2017 Aug)
- 215. Devita Surjana, Gary M Halliday, Andrew J Martin, Fergal J Moloney, Diona L Damian Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. *J Invest Dermatol.* (2012 May)
- 216. Francesco Drago, Giulia Ciccarese, Aurora Parodi <u>Nicotinamide for Skin-Cancer Chemoprevention</u>. *N Engl J Med.* (2016 Feb 25)
- 217. F Moloney, M Vestergaard, B Radojkovic, D Damian Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol. (2010 May)
- 218. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL <u>A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention</u>. *N Engl J Med*. (2015 Oct 22)
- 219. Stephen J Gilmore Nicotinamide and skin cancer chemoprevention: The jury is still out. Australas J Dermatol. (2018 Feb)
- 220. EFSA Panel on Dietetic Products Scientific Opinion on Dietary Reference Values for niacin. JEFSA. (2014 Jul)

- 221. Oldreive S <u>Safe intakes of vitamins and minerals</u>: recommendations from the Expert Group on Vitamins and Minerals. *Nutr. Bull.*. (2003 May)
- 222. B F Bourgeois, W E Dodson, J A Ferrendelli <u>Interactions between primidone, carbamazepine, and nicotinamide</u>. *Neurology*. (1982 Oct)
- 223. Brian Berman, Charles Ellis, Craig Elmets <u>Polypodium Leucotomos--An Overview of Basic Investigative Findings</u>. *J Drugs Dermatol.* (2016 Feb)
- 224. Middelkamp-Hup MA, Pathak MA, Parrado C, Goukassian D, Rius-Díaz F, Mihm MC, Fitzpatrick TB, González S Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. (2004 Dec)
- 225. Indermeet Kohli, Rubina Shafi, Prescilia Isedeh, James L Griffith, Mohammed S Al-Jamal, Narumol Silpa-Archa, Bradford Jackson, Mohammed Athar, Nikiforos Kollias, Craig A Elmets, Henry W Lim, Iltefat H Hamzavi The Impact of Oral Polypodium Leucotomos Extract on Ultraviolet B Response: A Human Clinical Study. J Am Acad Dermatol. (2017 Jul)
- 226. P Aguilera, C Carrera, J A Puig-Butille, C Badenas, M Lecha, S González, J Malvehy, S Puig Benefits of Oral Polypodium Leucotomos Extract in MM High-Risk Patients. *J Eur Acad Dermatol Venereol.* (2013 Sep)
- 227. Adriana Villa, Martha H Viera, Sadegh Amini, Ran Huo, Oliver Perez, Phillip Ruiz, Alexandra Amador, George Elgart, Brian Berman Decrease of Ultraviolet A Light-Induced "Common Deletion" in Healthy Volunteers After Oral Polypodium Leucotomos Extract Supplement in a Randomized Clinical Trial. J Am Acad Dermatol. (2010 Mar)
- 228. Maritza A Middelkamp-Hup, Madhu A Pathak, Concepcion Parrado, Tomas Garcia-Caballero, Francisca Rius-Díaz, Thomas B Fitzpatrick, Salvador González Orally Administered Polypodium Leucotomos Extract Decreases psoralen-UVA-induced Phototoxicity, Pigmentation, and Damage of Human Skin. J Am Acad Dermatol. (2004 Jan)
- 229. S González, M A Pathak, J Cuevas, V G Villarrubia, T B Fitzpatrick <u>Topical or Oral Administration With an Extract of Polypodium Leucotomos Prevents Acute Sunburn and Psoralen-Induced Phototoxic Reactions as Well as Depletion of Langerhans Cells in Human Skin. Photodermatol Photoimmunol Photomed. (Feb-Apr 1997)</u>
- 230. Enzo Emanuele, Marco Bertona, Marco Biagi <u>Comparative Effects of a Fixed Polypodium leucotomos/Pomegranate</u>

  <u>Combination Versus Polypodium Leucotomos Alone on Skin Biophysical Parameters.</u> *Neuro Endocrinol Lett.* (2017 Feb)
- 231. Mark S Nestor, Brian Berman, Nicole Swenson <u>Safety and Efficacy of Oral Polypodium Leucotomos Extract in Healthy Adult Subjects</u>. *J Clin Aesthet Dermatol*. (2015 Feb)
- 232. Adrian Tanew, Sonja Radakovic, Salvador Gonzalez, Marina Venturini, Piergiacomo Calzavara-Pinton Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption. J Am Acad Dermatol. (2012 Jan)
- 233. Matteo Auriemma, Marta Di Nicola, Salvador Gonzalez, Stefano Piaserico, Alessandra Capo, Paolo Amerio Polypodium leucotomos supplementation in the treatment of scalp actinic keratosis: could it improve the efficacy of photodynamic therapy?. Dermatol Surg. (2015 Aug)
- 234. Ammar M Ahmed, Isha Lopez, Francisco Perese, Rebecca Vasquez, Linda S Hynan, Benjamin Chong, Amit G Pandya <u>A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma</u>. *JAMA Dermatol.* (2013 Aug)
- 235. A Ramírez-Bosca, P Zapater, I Betlloch, F Albero, A Martínez, J Díaz-Alperi, J F Horga, Grupo de Anapsos en Dermatitis Atópica y centros de realización del estudio Polypodium leucotomos extract in atopic dermatitis: a randomized, double-blind, placebo-controlled, multicenter trial. Actas Dermosifiliogr. (2012 Sep)
- 236. Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W <u>Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study</u>. *J Eur Acad Dermatol Venereol*. (2007 Aug)
- 237. Caccialanza M, Percivalle S, Piccinno R, Brambilla R <u>Photoprotective activity of oral polypodium leucotomos extract in 25 patients with idiopathic photodermatoses</u>. *Photodermatol Photoimmunol Photomed*. (2007 Feb)
- 238. S González, M A Pathak Inhibition of ultraviolet-induced formation of reactive oxygen species, lipid peroxidation, erythema and skin photosensitization by polypodium leucotomos. *Photodermatol Photoimmunol Photomed.* (1996 Apr)
- 239. E J Samarasekera, L Sawyer, D Wonderling, R Tucker, C H Smith <u>Topical therapies for the treatment of plaque psoriasis:</u> systematic review and network meta-analyses. *Br J Dermatol.* (2013 May)
- 240. Fan Bai, Gang Gang Li, Qingmin Liu, Xinwu Niu, Ruilian Li, Huiqun Ma Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. (2019 Sep 10)
- 241. H Gollnick, A Menter Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. *Br J Dermatol.* (1999 Apr)
- 242. Natalya E Chalyk, Viktor A Klochkov, Tatiana Y Bandaletova, Nigel H Kyle, Ivan M Petyaev Continuous Astaxanthin Intake Reduces Oxidative Stress and Reverses Age-Related Morphological Changes of Residual Skin Surface Components in Middle-Aged Volunteers. Nutr Res. (2017 Dec)
- 243. Nicole M Lyons, Nora M O'Brien Modulatory Effects of an Algal Extract Containing Astaxanthin on UVA-irradiated Cells in Culture. J Dermatol Sci. (2002 Oct)
- 244. Tominaga K, Hongo N, Karato M, Yamashita E Cosmetic benefits of astaxanthin on humans subjects. Acta Biochim Pol. (2012)
- 245. Tominaga K, Hongo N, Fujishita M, Takahashi Y, Adachi Y Protective effects of astaxanthin on skin deterioration. J Clin

- Biochem Nutr. (2017 Jul)
- 246. Ito N, Seki S, Ueda F The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People-A Randomized, Double-Blind, Placebo-Controlled Trial. *Nutrients*. (2018 Jun 25)
- 247. A V Rawlings Cellulite and its treatment. Int J Cosmet Sci. (2006 Jun)
- 248. Sindy Trauer, Alexa Patzelt, Nina Otberg, Fanny Knorr, Christel Rozycki, Gabor Balizs, Rolf Büttemeyer, Michael Linscheid, Manfred Liebsch, Jürgen Lademann Permeation of topically applied caffeine through human skin--a comparison of in vivo and in vitro data. Br J Clin Pharmacol. (2009 Aug)
- 249. A Herman, A P Herman Caffeine's mechanisms of action and its cosmetic use. Skin Pharmacol Physiol. (2013)
- 250. T W Fischer, U C Hipler, P Elsner Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro. Int J Dermatol. (2007 Jan)
- 251. Allan H Conney, You-Rong Lou, Paul Nghiem, Jamie J Bernard, George C Wagner, Yao-Ping Lu Inhibition of UVB-induced nonmelanoma skin cancer: a path from tea to caffeine to exercise to decreased tissue fat. *Top Curr Chem.* (2013)
- 252. Sang-Young Byun, Soon-Hyo Kwon, Su-Hak Heo, Jae-Seong Shim, Mi-Hee Du, Jung-Im Na Efficacy of Slimming Cream Containing 3.5% Water-Soluble Caffeine and Xanthenes for the Treatment of Cellulite: Clinical Study and Literature Review. Ann Dermatol. (2015 Jun)
- 253. Anahita Vali, Ali Asilian, Elaheh Khalesi, Leila Khoddami, Mohammadali Shahtalebi, Maryam Mohammady <u>Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris</u>. *J Dermatolog Treat*. (2005)
- 254. R J Kaplan, L Daman, E W Rosenberg, S Feigenbaum <u>Topical use of caffeine with hydrocortisone in the treatment of atopic dermatitis</u>. *Arch Dermatol.* (1978 Jan)
- 255. Corinna Dressler, Anja Blumeyer, Stefanie Rosumeck, Anthony Arayesh, Alexander Nast Efficacy of topical caffeine in male androgenetic alopecia. *J Dtsch Dermatol Ges.* (2017 Jul)
- 256. V Gode, N Bhalla, V Shirhatti, S Mhaskar, Y Kamath Quantitative measurement of the penetration of coconut oil into human hair using radiolabeled coconut oil. *J Cosmet Sci.* (Jan-Feb 2012)
- 257. S B Ruetsch, Y K Kamath, A S Rele, R B Mohile <u>Secondary ion mass spectrometric investigation of penetration of coconut and mineral oils into human hair fibers: relevance to hair damage</u>. *J Cosmet Sci.* (May-Jun 2001)
- 258. K Keis, D Persaud, Y K Kamath, A S Rele <u>Investigation of penetration abilities of various oils into human hair fibers</u>. *J Cosmet Sci.* (Sep-Oct 2005)
- 259. K Keis, C L Huemmer, Y K Kamath Effect of oil films on moisture vapor absorption on human hair. J Cosmet Sci. (Mar-Apr 2007)
- 260. Sudhakar Mhaskar, Bhargavi Kalghatgi, Madhavi Chavan, Suryamani Rout, Vaishali Gode <u>Hair breakage index: an alternative</u> tool for damage assessment of human hair. *J Cosmet Sci.* (Mar-Apr 2011)
- 261. Frank Fischer, Volker Achterberg, Annette März, Stefan Puschmann, Christian-Dennis Rahn, Vivien Lutz, Andrea Krüger, Helge Schwengler, Sören Jaspers, Urte Koop, Thomas Blatt, Horst Wenck, Stefan Gallinat Folic acid and creatine improve the firmness of human skin in vivo. J Cosmet Dermatol. (2011 Mar)
- 262. Reto I Peirano, Volker Achterberg, Hans-Jürgen Düsing, Mehdi Akhiani, Urte Koop, Sören Jaspers, Andrea Krüger, Helge Schwengler, Tina Hamann, Horst Wenck, Franz Stäb, Stefan Gallinat, Thomas Blatt <u>Dermal penetration of creatine from a face-care formulation containing creatine, guarana and glycerol is linked to effective antiwrinkle and antisagging efficacy in male subjects. *J Cosmet Dermatol.* (2011 Dec)</u>
- 263. Roger de Moraes, Diogo Van Bavel, Beatriz Serpa de Moraes, Eduardo Tibiriçá Effects of dietary creatine supplementation on systemic microvascular density and reactivity in healthy young adults. *Nutr J.* (2014 Dec 15)
- 264. Anna J Nichols, Olivia Bosshardt Hughes, Agnese Canazza, Martin N Zaiac An Open-Label Evaluator Blinded Study of the Efficacy and Safety of a New Nutritional Supplement in Androgenetic Alopecia: A Pilot Study. J Clin Aesthet Dermatol. (2017 Feb)
- 265. A Eskelinin, J Santalahti Special natural cartilage polysaccharides for the treatment of sun-damaged skin in females. J Int Med Res. (1992 Apr)
- 266. A Lassus, L Jeskanen, H P Happonen, J Santalahti <u>Imedeen for the treatment of degenerated skin in females</u>. *J Int Med Res.* (Mar-Apr 1991)
- 267. Glynis Ablon A 6-month, randomized, double-blind, placebo-controlled study evaluating the ability of a marine complex supplement to promote hair growth in men with thinning hair. *J Cosmet Dermatol.* (2016 Dec)
- 268. Glynis Ablon A 3-month, randomized, double-blind, placebo-controlled study evaluating the ability of an extra-strength marine protein supplement to promote hair growth and decrease shedding in women with self-perceived thinning hair. *Dermatol Res Pract.* (2015)
- 269. Glynis Ablon, Steven Dayan A Randomized, Double-blind, Placebo-controlled, Multi-center, Extension Trial Evaluating the Efficacy of a New Oral Supplement in Women with Self-perceived Thinning Hair. J Clin Aesthet Dermatol. (2015 Dec)
- 270. Ronald L Rizer, Thomas J Stephens, James H Herndon, Brian R Sperber, James Murphy, Glynis R Ablon <u>A Marine Protein-based Dietary Supplement for Subclinical Hair Thinning/Loss: Results of a Multisite, Double-blind, Placebo-controlled Clinical Trial. Int J Trichology. (Oct-Dec 2015)</u>
- 271. Ablon Glynis A Double-blind, Placebo-controlled Study Evaluating the Efficacy of an Oral Supplement in Women with Self-perceived Thinning Hair. J Clin Aesthet Dermatol. (2012 Nov)

- 272. E Thom Efficacy and tolerability of Hairgain in individuals with hair loss: a placebo-controlled, double-blind study. J Int Med Res. (Jan-Feb 2001)
- 273. A Lassus, E Eskelinen A comparative study of a new food supplement, ViviScal, with fish extract for the treatment of hereditary androgenic alopecia in young males. J Int Med Res. (1992 Nov)
- 274. Pereira J <u>Treatment of Androgenetic Alopecia with a Marine-Based Extract of Proteins and Polysaccharides</u>. *Revista Brasileira De Medicina*. (1997 Mar)
- 275. Majass M et al. Treatment of Alopecia Areata, Alopecia Totalis and Alopecia Universalis with Oral ViviScal® for 12 Months.
- 276. Lassus A et al. Treatment of Alopecia Areata and Alopecia Totalis With Viviscal® (Special Marine Extract Compound).
- 277. Lassus A et al. <u>Treatment of Hereditary Androgenic Alopecia in Middle-Aged Males by Combined Oral and Topical Administration of Special Marine Extract-Compound</u>. *Les Nouvelles Dermatologiques*. (1994)
- 278. Stephens T et al. An 10-week pilot consumer perception test to evaluate the overall acceptability of a Viviscal oral supplement when used by females with self-perceived thinning hair.
- 279. Mrinal Gupta, Venkataram Mysore Classifications of Patterned Hair Loss: A Review. J Cutan Aesthet Surg. (Jan-Mar 2016)
- 280. Kumpol Aiempanakit, Alan Geater, Preeyachat Limtong, Kathleen Nicoletti <u>The use of topical minoxidil to accelerate nail growth: a pilot study</u>. *Int J Dermatol.* (2017 Jul)
- 281. Jenna R Stoehr, Jennifer N Choi, Maria Colavincenzo, Stefan Vanderweil Off-Label Use of Topical Minoxidil in Alopecia: A Review. Am J Clin Dermatol. (2019 Apr)
- 282. Akira Kawada, Natsuko Konishi, Naoki Oiso, Shigeru Kawara, Akira Date <u>Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide</u>. *J Dermatol.* (2008 Oct)
- 283. Bissett DL, Oblong JE, Berge CA Niacinamide: A B vitamin that improves aging facial skin appearance. *Dermatol Surg.* (2005 Jul)
- 284. Josefina Navarrete-Solís, Juan Pablo Castanedo-Cázares, Bertha Torres-Álvarez, Cuauhtemoc Oros-Ovalle, Cornelia Fuentes-Ahumada, Francisco Javier González, Juan David Martínez-Ramírez, Benjamin Moncada <u>A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma</u>. *Dermatol Res Pract.* (2011)
- 285. Danielle Levine, Zeev Even-Chen, Irina Lipets, Olga A Pritulo, Tetyana V Svyatenko, Yuri Andrashko, Mark Lebwohl, Alice Gottlieb Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. *J Am Acad Dermatol.* (2010 Nov)
- 286. Yoshinao Soma, Masato Kashima, Akiko Imaizumi, Hideto Takahama, Tamihiro Kawakami, Masako Mizoguchi Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol. (2005 Mar)
- 287. D P Fivenson, D L Breneman, G B Rosen, C S Hersh, S Cardone, D Mutasim <u>Nicotinamide and tetracycline therapy of bullous pemphigoid</u>. *Arch Dermatol.* (1994 Jun)
- 288. D N Kolbach, J J Remme, W H Bos, M F Jonkman, M C De Jong, H H Pas, J B van der Meer <u>Bullous pemphigoid successfully controlled by tetracycline and nicotinamide</u>. *Br J Dermatol.* (1995 Jul)
- 289. B A Honl, D M Elston <u>Autoimmune bullous eruption localized to a breast reconstruction site: response to niacinamide</u>. *Cutis*. (1998 Aug)
- 290. Xiao-Feng Shan, Fu-Ren Zhang, Hong-Qing Tian, Na Wang, Sheng-Ji Zhou, Guang-Jin Wang <u>A case of linear IgA dermatosis successfully treated with tetracycline and niacinamide</u>. *Int J Dermatol*. (2016 Apr)
- 291. M Yomada, A Komai, T Hashimato <u>Sublamina densa-type linear IgA bullous dermatosis successfully treated with oral tetracycline and niacianamide</u>. *Br J Dermatol.* (1999 Sep)
- 292. Mohammad Omidian, Ahmad Khazanee, Reza Yaghoobi, Ali Reza Ghorbani, Nader Pazyar, Seyed Seifollah Beladimousavi, Mahmoodreza Ghadimi, Alireza Mohebbipour, Amir Feily <u>Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study</u>. Saudi J Kidney Dis Transpl. (2013 Sep)
- 293. Patricia K Farris, Nicole Rogers, Amy McMichael, Sophia Kogan <u>A Novel Multi-Targeting Approach to Treating Hair Loss, Using Standardized Nutraceuticals</u>. *J Drugs Dermatol*. (2017 Nov 1)
- 294. Glynis Ablon, Sophia Kogan A Six-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Women With Self-Perceived Thinning Hair. J Drugs Dermatol. (2018 May 1)
- 295. Glynis Ablon, Sophia Kogan A Randomized, Double-Blind, Placebo-Controlled Study of a Nutraceutical Supplement for Promoting Hair Growth in Perimenopausal, Menopausal, and Postmenopausal Women With Thinning Hair. J Drugs Dermatol. (2021 Jan 1)
- 296. Caccialanza M, Recalcati S, Piccinno R <u>Oral polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses</u>. *G Ital Dermatol Venereol.* (2011 Apr)
- 297. J G Smith The journal of the American Academy of Dermatology. Int J Dermatol. (Jul-Aug 1979)
- 298. Eduardo Reyes, Pedro Jaén, Elena de las Heras, Flavio Carrión, Melchor Alvarez-Mon, Ester de Eusebio, M Alvare, Jesús Cuevas, Salvador González, Vicente G Villarrubia Systemic immunomodulatory effects of Polypodium leucotomos as an adjuvant to PUVA therapy in generalized vitiligo: A pilot study. J Dermatol Sci. (2006 Mar)
- 299. Pacifico A Combined treatment of narrowband ultraviolet B light (NBUVB) phototherapy and oral polypodium leucotomos

- extract versus NB UVB phototherapy alone in the treatment of patients with vitiligo. JAAD. (2009 Mar)
- 300. Padilla HC, Laínez H, Pacheco JA A new agent (hydrophilic fraction of polypodium leucotomos) for management of psoriasis. Int J Dermatol. (1974 Sep-Oct)
- 301. D Jiménez, R Naranjo, E Doblaré, C Muñoz, J F Vargas <u>Anapsos, an antipsoriatic drug, in atopic dermatitis</u>. *Allergol Immunopathol (Madr)*. (Jul-Aug 1987)
- 302. Neena Philips, Jennifer Conte, Yu-Jun Chen, Prashanti Natrajan, May Taw, Thomas Keller, Joshua Givant, Marvin Tuason, Luiji Dulaj, Donna Leonardi, Salvador Gonzalez Beneficial regulation of matrixmetalloproteinases and their inhibitors, fibrillar collagens and transforming growth factor-beta by Polypodium leucotomos, directly or in dermal fibroblasts, ultraviolet radiated fibroblasts, and melanoma cells. Arch Dermatol Res. (2009 Aug)
- 303. Neena Philips, Joan Smith, Thomas Keller, Salvador Gonzalez Predominant effects of Polypodium leucotomos on membrane integrity, lipid peroxidation, and expression of elastin and matrixmetalloproteinase-1 in ultraviolet radiation exposed fibroblasts, and keratinocytes. J Dermatol Sci. (2003 Jun)
- 304. Truchuelo M et al. Pilot study to assess the effects of a new oral photoprotector against infrared-visible radiations. *J. Invest. Dermatol.*. (2016 May)
- 305. Vitória H M Mottin, Edna S Suyenaga An approach on the potential use of probiotics in the treatment of skin conditions: acne and atopic dermatitis. Int J Dermatol. (2018 Dec)
- 306. Justine Fenner, Nanette B Silverberg Oral supplements in atopic dermatitis. Clin Dermatol. (Sep-Oct 2018)
- 307. H Cevdet Altinyazar, Rafet Koca, Nilgün Solak Tekin, Emel Eştürk <u>Adapalene vs. metronidazole gel for the treatment of rosacea</u>. *Int J Dermatol.* (2005 Mar)
- 308. G A Ertl, N Levine, A M Kligman A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. *Arch Dermatol.* (1994 Mar)
- 309. Harald Gollnick, Ulrike Blume-Peytavi, Eörs Lāszlō Szabó, Karl-Gustav Meyer, Petra Hauptmann, Georg Popp, Michael Sebastian, Thomas Zwingers, Christoph Willers, Renate von der Weth Systemic isotretinoin in the treatment of rosacea doxycycline- and placebo-controlled, randomized clinical study. *J Dtsch Dermatol Ges.* (2010 Jul)
- 310. F Anzengruber, J Czernielewski, C Conrad, L Feldmeyer, N Yawalkar, P Häusermann, A Cozzio, C Mainetti, D Goldblum, S Läuchli, L Imhof, C Brand, E Laffitte, A A Navarini Swiss S1 guideline for the treatment of rosacea. *J Eur Acad Dermatol Venereol.* (2017 Nov)
- 311. Yuka Asai, Jerry Tan, Akerke Baibergenova, Benjamin Barankin, Chris L Cochrane, Shannon Humphrey, Charles W Lynde, Danielle Marcoux, Yves Poulin, Jason K Rivers, Mariusz Sapijaszko, R Gary Sibbald, John Toole, Marcie Ulmer, Catherine Zip Canadian Clinical Practice Guidelines for Rosacea. J Cutan Med Surg. (2016 Sep)
- 312. L L Hruza, A P Pentland Mechanisms of UV-induced Inflammation. J Invest Dermatol. (1993 Jan)
- 313. A Pérez-Sánchez, E Barrajón-Catalán, N Caturla, J Castillo, O Benavente-García, M Alcaraz, V Micol <u>Protective Effects of Citrus and Rosemary Extracts on UV-induced Damage in Skin Cell Model and Human Volunteers</u>. *J Photochem Photobiol B.* (2014 Jul 5)
- 314. Vincenzo Nobile, Angela Michelotti, Enza Cestone, Nuria Caturla, Julián Castillo, Obdulio Benavente-García, Almudena Pérez-Sánchez, Vicente Micol Skin Photoprotective and Antiageing Effects of a Combination of Rosemary (Rosmarinus Officinalis) and Grapefruit (Citrus Paradisi) Polyphenols. Food Nutr Res. (2016 Jul 1)
- 315. Soleymani T, Lo Sicco K, Shapiro J <u>The Infatuation With Biotin Supplementation: Is There Truth Behind Its Rising Popularity? A Comparative Analysis of Clinical Efficacy versus Social Popularity.</u> *J Drugs Dermatol.* (2017 May 1)
- 316. John JJ, Cooley V, Lipner SR <u>Assessment of biotin supplementation among patients in an outpatient dermatology clinic</u>. *J Am Acad Dermatol*. (2019 Aug)
- 317. Patel DP, Swink SM, Castelo-Soccio L A Review of the Use of Biotin for Hair Loss. Skin Appendage Disord. (2017 Aug)
- 318. Trüeb RM Serum Biotin Levels in Women Complaining of Hair Loss. Int J Trichology. (2016 Apr-Jun)
- 319. Zempleni J, Hassan YI, Wijeratne SS Biotin and biotinidase deficiency. Expert Rev Endocrinol Metab. (2008 Nov 1)
- 320. Lipner SR, Scher RK Biotin for the treatment of nail disease: what is the evidence?. J Dermatolog Treat. (2018 Jun)
- 321. Colombo VE, Gerber F, Bronhofer M, Floersheim GL <u>Treatment of brittle fingernails and onychoschizia with biotin: scanning electron microscopy</u>. *J Am Acad Dermatol.* (1990 Dec)
- 322. Hochman LG, Scher RK, Meyerson MS Brittle nails: response to daily biotin supplementation. Cutis. (1993 Apr)
- 323. Gloster H Jr, Kindred C <u>Habit-tic-like and median nail-like dystrophies treated with multivitamins</u>. *J Am Acad Dermatol.* (2005 Sep)
- 324. Piraccini B et al Triangular worn-down nails: Report of 14 cases. G Ital Dermatol Venereol. (2005 Jan)
- 325. Möhrenschlager M et al. Recalcitrant trachyonychia of childhood response to daily oral biotin supplementation: report of two cases. J Dermatolog Treat. (2009 Jul)
- 326. Boccaletti V, Zendri E, Giordano G, Gnetti L, De Panfilis G <u>Familial Uncombable Hair Syndrome: Ultrastructural Hair Study and Response to Biotin</u>. *Pediatr Dermatol.* (2007 May-Jun)
- 327. Shelley WB, Shelley ED <u>Uncombable hair syndrome: observations on response to biotin and occurrence in siblings with ectodermal dysplasia</u>. *J Am Acad Dermatol.* (1985 Jul)

- 328. Mercke Y, Sheng H, Khan T, Lippmann S Hair loss in psychopharmacology. Ann Clin Psychiatry. (2000 Mar)
- 329. Schulpis KH, Karikas GA, Tjamouranis J, Regoutas S, Tsakiris S <u>Low serum biotinidase activity in children with valproic acid monotherapy</u>. *Epilepsia*. (2001 Oct)
- 330. Wang X, Wang H, Xu D, Zhu L, Liu L Risk of valproic acid-related alopecia: A systematic review and meta-analysis. Seizure. (2019 Jul)
- 331. BES Research Group Effects of Combination Therapy with Vitamins E and B2 on Skin Diseases. Skin. (1989)
- 332. G M Fairris, P J Perkins, B Lloyd, L Hinks, B E Clayton The effect on atopic dermatitis of supplementation with selenium and vitamin E. Acta Derm Venereol. (1989)
- 333. Evridiki Tsoureli-Nikita, Jana Hercogova, Torello Lotti, Giovanni Menchini Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels. Int J Dermatol. (2002 Mar)
- 334. Annalisa Patrizi, Beatrice Raone, Iria Neri, Carlotta Gurioli, Monica Carbonara, Nicoletta Cassano, Gino Antonio Vena Randomized, controlled, double-blind clinical study evaluating the safety and efficacy of MD2011001 cream in mild-to-moderate atopic dermatitis of the face and neck in children, adolescents and adults. *J Dermatolog Treat*. (2016 Aug)
- 335. Mohammad Hassan Javanbakht, Seyed Ali Keshavarz, Mahmoud Djalali, Fereydoun Siassi, Mohammad Reza Eshraghian, Alireza Firooz, Hassan Seirafi, Amir Hooshang Ehsani, Maryam Chamari, Abbas Mirshafiey Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. J Dermatolog Treat. (2011 Jun)
- 336. A Wollenberg, S Barbarot, T Bieber, S Christen-Zaech, M Deleuran, A Fink-Wagner, U Gieler, G Girolomoni, S Lau, A Muraro, M Czarnecka-Operacz, T Schäfer, P Schmid-Grendelmeier, D Simon, Z Szalai, J C Szepietowski, A Taïeb, A Torrelo, T Werfel, J Ring, European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients' Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. (2018 May)
- 337. Beoy LA, Woei WJ, Hay YK Effects of tocotrienol supplementation on hair growth in human volunteers. *Trop Life Sci Res.* (2010 Dec)
- 338. Caroline Le Floc'h, Ahsène Cheniti, Sophie Connétable, Nathalie Piccardi, Colombina Vincenzi, Antonella Tosti <u>Effect of a nutritional supplement on hair loss in women.</u> *J Cosmet Dermatol.* (2015 Mar)
- 339. Moers-Carpi M Influence of Nutritive Factors on Hair Growth. Akt Dermatol. (2011)
- 340. S Ayres Jr, R Mihan Yellow nail syndrome: response to vitamin E. Arch Dermatol. (1973 Aug)
- 341. Robert Baran, Luc Thomas <u>Combination of fluconazole and alpha-tocopherol in the treatment of yellow nail syndrome</u>. *J Drugs Dermatol.* (2009 Mar)
- 342. Fabien Maldonado, Henry D Tazelaar, Chih-Wei Wang, Jay H Ryu Yellow nail syndrome: analysis of 41 consecutive patients. Chest. (2008 Aug)
- 343. Emily M Lambert, James Dziura, Lynda Kauls, Mark Mercurio, Richard J Antaya <u>Yellow nail syndrome in three siblings: a randomized double-blind trial of topical vitamin E. Pediatr Dermatol.</u> (Jul-Aug 2006)
- 344. Renata Strumia Dermatologic signs in patients with eating disorders. Am J Clin Dermatol. (2005)
- 345. Aleksandar Godic, Borut Poljšak, Metka Adamic, Raja Dahmane <u>The Role of Antioxidants in Skin Cancer Prevention and Treatment</u>. Oxid Med Cell Longev. (2014)
- 346. Jens J Thiele, Swarna Ekanayake-Mudiyanselage <u>Vitamin E in Human Skin: Organ-Specific Physiology and Considerations for Its Use in Dermatology</u>. *Mol Aspects Med.* (Oct-Dec 2007)
- 347. Alexandra Mereniuk, Philippe Marchessault, Catherine Maari, Chantal Bolduc, Robert Bissonnette <u>Topical Vitamin E Cream Does Not Prevent Visible Light-Induced Pigmentation</u>. *J Cutan Med Surg*. (Jan/Feb 2018)
- 348. Wei Ney Yap Tocotrienol-rich Fraction Attenuates UV-induced Inflammaging: A Bench to Bedside Study. J Cosmet Dermatol. (2018 Jun)
- 349. Jin Ho Chung, Jin Young Seo, Mi Kyoung Lee, Hee Chul Eun, Joo Heung Lee, Sewon Kang, Gary J Fisher, John J Voorhees Ultraviolet Modulation of Human Macrophage Metalloelastase in Human Skin in Vivo. J Invest Dermatol. (2002 Aug)
- 350. F Dreher, N Denig, B Gabard, D A Schwindt, H I Maibach Effect of Topical Antioxidants on UV-induced Erythema Formation When Administered After Exposure. *Dermatology*. (1999)
- 351. L Montenegro, F Bonina, L Rigano, S Giogilli, S Sirigu Protective Effect Evaluation of Free Radical Scavengers on UVB Induced Human Cutaneous Erythema by Skin Reflectance Spectrophotometry. Int J Cosmet Sci. (1995 Jun)
- 352. Frank McArdle, Lesley E Rhodes, Richard A G Parslew, Graeme L Close, Catherine I A Jack, Peter S Friedmann, Malcolm J Jackson Effects of Oral Vitamin E and Beta-Carotene Supplementation on Ultraviolet Radiation-Induced Oxidative Stress in Human Skin. Am J Clin Nutr. (2004 Nov)
- 353. Homero Mireles-Rocha, Ignacio Galindo, Miguel Huerta, Benjamín Trujillo-Hernández, Alejandro Elizalde, Roberto Cortés-Franco UVB Photoprotection With Antioxidants: Effects of Oral Therapy With D-Alpha-Tocopherol and Ascorbic Acid on the Minimal Erythema Dose. Acta Derm Venereol. (2002)

- 354. W Stahl, U Heinrich, H Jungmann, H Sies, H Tronnier <u>Carotenoids and Carotenoids Plus Vitamin E Protect Against Ultraviolet Light-Induced Erythema in Humans</u>. *Am J Clin Nutr*. (2000 Mar)
- 355. B Eberlein-König, M Placzek, B Przybilla Protective Effect Against Sunburn of Combined Systemic Ascorbic Acid (Vitamin C) and D-Alpha-Tocopherol (Vitamin E). J Am Acad Dermatol. (1998 Jan)
- 356. K Werninghaus, M Meydani, J Bhawan, R Margolis, J B Blumberg, B A Gilchrest <u>Evaluation of the Photoprotective Effect of Oral Vitamin E Supplementation</u>. *Arch Dermatol.* (1994 Oct)
- 357. Oliver A Perez, Martha H Viera, Jitendra K Patel, Sailesh Konda, Sadegh Amini, Ran Huo, Deborah Zell, Sujatha Tadicherla, Brian Berman A comparative study evaluating the tolerability and efficacy of two topical therapies for the treatment of keloids and hypertrophic scars. J Drugs Dermatol. (2010 May)
- 358. B Palmieri, G Gozzi, G Palmieri <u>Vitamin E added silicone gel sheets for treatment of hypertrophic scars and keloids</u>. *Int J Dermatol.* (1995 Jul)
- 359. Baumann LS, Spencer J The effects of topical vitamin E on the cosmetic appearance of scars. Dermatol Surg. (1999 Apr.)
- 360. Jenkins M, Alexander JW, MacMillan BG, Waymack JP, Kopcha R <u>Failure of topical steroids and vitamin E to reduce postoperative scar formation following reconstructive surgery</u>. *J Burn Care Rehabil*. (1986 Jul-Aug)
- 361. T L Khoo, A S Halim, Z Zakaria, A Z Mat Saad, L Y Wu, H Y Lau A prospective, randomised, double-blinded trial to study the efficacy of topical tocotrienol in the prevention of hypertrophic scars. J Plast Reconstr Aesthet Surg. (2011 Jun)
- 362. T Mitsuishi, T Shimoda, Y Mitsui, Y Kuriyama, S Kawana <u>The effects of topical application of phytonadione, retinol and vitamins</u>
  <u>C and E on infraorbital dark circles and wrinkles of the lower eyelids.</u> *J Cosmet Dermatol.* (2004 Apr)
- 363. Shah NS, Lazarus MC, Bugdodel R, Hsia SL, He J, Duncan R, Baumann L <u>The effects of topical vitamin K on bruising after laser treatment</u>. *J Am Acad Dermatol*. (2002 Aug)
- 364. W W Lou, A T Quintana, R G Geronemus, M C Grossman Effects of topical vitamin K and retinol on laser-induced purpura on nonlesional skin. *Dermatol Surg.* (1999 Dec)
- 365. Janja Ocvirk Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream. Radiol Oncol. (2010 Dec)
- 366. Jesper Grau Eriksen, Inger Kaalund, Ole Clemmensen, Jens Overgaard, Per Pfeiffer Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer. (2017 Jul)
- 367. Cohen JL, Bhatia AC <u>The role of topical vitamin K oxide gel in the resolution of postprocedural purpura</u>. *J Drugs Dermatol.* (2009 Nov)
- 368. R-D Hofheinz, S Lorenzen, J Trojan, J Ocvirk, T J Ettrich, S-E Al-Batran, H Schulz, N Homann, H-P Feustel, M Schatz, M Kripp, N Schulte, M Tetyusheva, S Heeger, S Vlassak, K Merx EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Ann Oncol. (2018 Apr 1)
- 369. Staci Brandt The clinical effects of zinc as a topical or oral agent on the clinical response and pathophysiologic mechanisms of acne: a systematic review of the literature. J Drugs Dermatol. (2013 May)
- 370. Jessica Cervantes, Ariel E Eber, Marina Perper, Vanessa M Nascimento, Keyvan Nouri, Jonette E Keri <u>The role of zinc in the treatment of acne: A review of the literature</u>. *Dermatol Ther*. (2018 Jan)
- 371. Institute of Medicine (US) Panel on Micronutrients <u>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc.</u>
- 372. S P Nations, P J Boyer, L A Love, M F Burritt, J A Butz, G I Wolfe, L S Hynan, J Reisch, J R Trivedi <u>Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease</u>. *Neurology*. (2008 Aug 26)
- 373. Duncan A, Yacoubian C, Watson N, Morrison I <u>The risk of copper deficiency in patients prescribed zinc supplements</u>. *J Clin Pathol.* (2015 Sep)
- 374. Bamford JT, Gessert CE, Haller IV, Kruger K, Johnson BP Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. Int J Dermatol. (2012 Apr)
- 375. Sharquie KE, Najim RA, Al-Salman HN <u>Oral zinc sulfate in the treatment of rosacea: a double-blind, placebo-controlled study</u>. *Int J Dermatol.* (2006 Jul)
- 376. Sadeghian G, Ziaei H, Nilforoushzadeh MA <u>Treatment of localized psoriasis with a topical formulation of zinc pyrithione</u>. *Acta Dermatovenerol Alp Panonica Adriat*. (2011)
- 377. N P Burrows, A J Turnbull, N A Punchard, R P Thompson, R R Jones <u>A trial of oral zinc supplementation in psoriasis</u>. *Cutis*. (1994 Aug)
- 378. C I Ewing, A C Gibbs, C Ashcroft, T J David Failure of oral zinc supplementation in atopic eczema. Eur J Clin Nutr. (1991 Oct)
- 379. Jeong Eun Kim, Seo Rye Yoo, Myeong Gil Jeong, Joo Yeon Ko, Young Suck Ro <u>Hair zinc levels and the efficacy of oral zinc supplementation in patients with atopic dermatitis</u>. *Acta Derm Venereol*. (2014 Sep)
- 380. Mrinal Gupta, Vikram K Mahajan, Karaninder S Mehta, Pushpinder S Chauhan Zinc therapy in dermatology: a review. *Dermatol Res Pract.* (2014)
- 381. S Gause, A Chauhan <u>UV-blocking Potential of Oils and Juices</u>. Int J Cosmet Sci. (2016 Aug)
- 382. C J D ZARAFONETIS Darkening of gray hair during para-amino-benzoic acid therapy. J Invest Dermatol. (1950 Dec)

- 383. B F Sieve CLINICAL ACHROMOTRICHIA. Science. (1941 Sep 12)
- 384. Brandaleone H et al. Effect of Calcium Pantothenate and Para-Aminobenzoic Acid on the Gray Hair of Humans. Exp. Biol. Med.. (1943 May)
- 385. P Bernhardt, M Giesen, D Hollenberg, M Hubbuch, V Kalhöfer, H E Maier, V Martin, H P Münzing, T Oelschläger, A Schwan, K Sperling, J Tennigkeit <u>UV filters for hair protection</u>. *Int J Cosmet Sci.* (1993 Oct)
- 386. Bikle DD Vitamin D metabolism and function in the skin. Mol Cell Endocrinol. (2011 Dec 5)
- 387. A Faurschou, D M Beyer, A Schmedes, M K Bogh, P A Philipsen, H C Wulf The relation between sunscreen layer thickness and vitamin D production after ultraviolet B exposure: a randomized clinical trial. Br J Dermatol. (2012 Aug)
- 388. Libon F, Courtois J, Le Goff C, Lukas P, Fabregat-Cabello N, Seidel L, Cavalier E, Nikkels AF Sunscreens block cutaneous vitamin D production with only a minimal effect on circulating 25-hydroxyvitamin D. Arch Osteoporos. (2017 Dec)
- 389. R E Neale, S R Khan, R M Lucas, M Waterhouse, D C Whiteman, C M Olsen <u>The effect of sunscreen on vitamin D: a review</u>. Br J Dermatol. (2019 Nov)
- 390. T Passeron, R Bouillon, V Callender, T Cestari, T L Diepgen, A C Green, J C van der Pols, B A Bernard, F Ly, F Bernerd, L Marrot, M Nielsen, M Verschoore, N G Jablonski, A R Young Sunscreen photoprotection and vitamin D status. Br J Dermatol. (2019 Nov)
- 391. Barbara B Shih, Mark D Farrar, Marcus S Cooke, Joanne Osman, Abigail K Langton, Richard Kift, Ann R Webb, Jacqueline L Berry, Rachel E B Watson, Andy Vail, Frank R de Gruijl, Lesley E Rhodes <u>Fractional Sunburn Threshold UVR Doses Generate Equivalent Vitamin D and DNA Damage in Skin Types I-VI but with Epidermal DNA Damage Gradient Correlated to Skin Darkness.</u> J Invest Dermatol. (2018 Oct)
- 392. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, A Catharine Ross, Christine L Taylor, Ann L Yaktine, Heather B Del Valle <u>Dietary Reference Intakes for Calcium and Vitamin D</u>.
- 393. A R Webb, B R DeCosta, M F Holick <u>Sunlight regulates the cutaneous production of vitamin D3 by causing its photodegradation</u>. *J Clin Endocrinol Metab*. (1989 May)
- 394. Wacker M, Holick MF Sunlight and Vitamin D: A global perspective for health. Dermatoendocrinol. (2013 Jan 1)
- 395. Engelsen O, Kylling A Fast simulation tool for ultraviolet radiation at the earth \$\&\pmu039\$;s surface. Opt Eng. (2005 Apr)
- 396. John C Dowdy, Robert M Sayre, Michael F Holick Holick's rule and vitamin D from sunlight. J Steroid Biochem Mol Biol. (2010 Jul)
- 397. Vitaly Terushkin, Anna Bender, Estee L Psaty, Ola Engelsen, Steven Q Wang, Allan C Halpern <u>Estimated equivalency of vitamin D production from natural sun exposure versus oral vitamin D supplementation across seasons at two US latitudes</u>. *J Am Acad Dermatol.* (2010 Jun)
- 398. Ann R Webb, Ola Engelsen <u>Calculated ultraviolet exposure levels for a healthy vitamin D status</u>. *Photochem Photobiol.* (Nov-Dec 2006)
- 399. I R Reid Calcium supplements and nail quality. N Engl J Med. (2000 Dec 14)
- 400. Noah Scheinfeld, Maurice J Dahdah, Richard Scher <u>Vitamins and minerals: their role in nail health and disease</u>. *J Drugs Dermatol.* (2007 Aug)
- 401. Chanchal Deep Kaur, Swarnlata Saraf <u>In Vitro Sun Protection Factor Determination of Herbal Oils Used in Cosmetics</u>. *Pharmacognosy Res.* (2010 Jan)
- 402. David A Kiken, David E Cohen Contact Dermatitis to Botanical Extracts. Am J Contact Dermat. (2002 Sep)
- 403. M Corazza, A Borghi, M M Lauriola, A Virgili <u>Use of Topical Herbal Remedies and Cosmetics: A Questionnaire-Based</u>
  <u>Investigation in Dermatology Out-Patients.</u> *J Eur Acad Dermatol Venereol.* (2009 Nov)
- 404. Courtney Blair Rubin, Bruce Brod Natural Does Not Mean Safe-The Dirt on Clean Beauty Products. JAMA Dermatol. (2019 Sep 25)
- 405. van der Merwe J, Brooks NE, Myburgh KH <u>Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players</u>. *Clin J Sport Med.* (2009 Sep)
- 406. Hamada K, Randall VA Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness. Br J Dermatol. (2006 Apr)
- 407. Trüeb RM Molecular mechanisms of androgenetic alopecia. Exp Gerontol. (2002 Aug-Sep)
- 408. Vatani DS, Faraji H, Soori R, Mogharnasi R <u>The Effects of Creatine Supplementation on Performance and Hormonal Response in Amateur Swimmers</u>. *Science and Sports*. (2011 Nov)
- 409. Arazi H, Rahmaninia F, Hosseini K, Asadi A <u>Effects of short term creatine supplementation and resistance exercises on resting hormonal and cardiovascular responses</u>. *Science and Sports*. (2015 Apr)
- 410. Cooke MB, Brabham B, Buford TW, Shelmadine BD, McPheeters M, Hudson GM, Stathis C, Greenwood M, Kreider R, Willoughby DS <u>Creatine supplementation post-exercise does not enhance training-induced adaptations in middle to older aged males</u>. *Eur J Appl Physiol.* (2014 Jun)
- 411. Cook CJ, Crewther BT, Kilduff LP, Drawer S, Gaviglio CM Skill execution and sleep deprivation: effects of acute caffeine or creatine supplementation a randomized placebo-controlled trial. J Int Soc Sports Nutr. (2011 Feb 16)
- 412. Crowe MJ, O'Connor DM, Lukins JE The effects of beta-hydroxy-beta-methylbutyrate (HMB) and HMB/creatine

- supplementation on indices of health in highly trained athletes. Int J Sport Nutr Exerc Metab. (2003 Jun)
- 413. Hoffman J, Ratamess N, Kang J, Mangine G, Faigenbaum A, Stout J <u>Effect of creatine and beta-alanine supplementation on performance and endocrine responses in strength/power athletes. *Int J Sport Nutr Exerc Metab.* (2006 Aug)</u>
- 414. Eijnde BO, Hespel P Short-term creatine supplementation does not alter the hormonal response to resistance training. *Med Sci Sports Exerc.* (2001 Mar)
- 415. Volek JS, Ratamess NA, Rubin MR, Gómez AL, French DN, McGuigan MM, Scheett TP, Sharman MJ, Häkkinen K, Kraemer WJ

  The effects of creatine supplementation on muscular performance and body composition responses to short-term resistance
  training overreaching. Eur J Appl Physiol. (2004 May)
- 416. Faraji H, Arazi H, Vatani D, Hakimi M The effects of creatine supplementation on sprint running performance and selected hormonal responses. SAJRSPER. (2010)
- 417. Rahimi R, Faraji H, Vatani DS, Qaderi M <u>Creatine supplementation alters the hormonal response to resistance exercise</u>. *Kinesiology*. (2010)
- 418. Volek JS, Boetes M, Bush JA, Putukian M, Sebastianelli W, Wayne J, Kraemer, WJ Response of Testosterone and Cortisol Concentrations to High-Intensity Resistance Exercise Following Creatine Supplementation. *JSCR.* (1997 Ayg)
- 419. Wilson JM, Lowery RP, Joy JM, Walters JA, Baier SM, Fuller JC, Stout JR, Norton LE, Sikorski EM, Wilson SM, Duncan NM, Zanchi NE, Rathmacher J β-Hydroxy-β-methylbutyrate free acid reduces markers of exercise-induced muscle damage and improves recovery in resistance-trained men. *Br J Nutr.* (2013 Jan 3)
- 420. Hoffman JR, Cooper J, Wendell M, Im J, Kang J <u>Effects of beta-hydroxy beta-methylbutyrate on power performance and indices of muscle damage and stress during high-intensity training</u>. *J Strength Cond Res.* (2004 Nov)
- 421. Portal S, Zadik Z, Rabinowitz J, Pilz-Burstein R, Adler-Portal D, Meckel Y, Cooper DM, Eliakim A, Nemet D The effect of HMB supplementation on body composition, fitness, hormonal and inflammatory mediators in elite adolescent volleyball players: a prospective randomized, double-blind, placebo-controlled study. Eur J Appl Physiol. (2011 Sep)
- 422. Slater GJ, Logan PA, Boston T, Gore CJ, Stenhouse A, Hahn AG <u>Beta-hydroxy beta-methylbutyrate (HMB) supplementation does not influence the urinary testosterone: epitestosterone ratio in healthy males.</u> *J Sci Med Sport.* (2000 Mar)